Drugs for the treatment of nonalcoholic fatty liver disease

Insulin resistance and lipid metabolism disorders in NAFLD treatment were solved by using polypeptides derived from HBV, especially pre-S1 region polypeptides in HBV genotypes A, B, C, D, E, F, G and H. , effective treatment of NAFLD was achieved, significantly improving liver and metabolic status.

CN111225680BActive Publication Date: 2024-11-08SHANGHAI HEP PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880067640.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-10-18
Filing Date
2018-10-18
Publication Date
2024-11-08
Estimated Expiration
2038-10-18

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat non-alcoholic fatty liver disease (NAFLD), especially because the progression of disease caused by insulin resistance and lipid metabolism disorders is difficult to control, and the existing treatment methods have limited efficacy.

Method used

Using polypeptides derived from HBV, especially polypeptides from the pre-S1 region of HBV genotypes A, B, C, D, E, F, G and H, through different modifications such as N-terminal and C-terminal modifications, A biologically active pharmaceutical composition is formed for the treatment of NAFLD, including simple fatty liver, non-alcoholic steatohepatitis, fatty liver fibrosis and cirrhosis.

Benefits of technology

This polypeptide composition can significantly reduce NAFLD-related symptoms, improve insulin resistance, reduce liver and serum fat accumulation, reduce liver fibrosis, increase total bile acid level, reduce blood albumin and cholesterol levels, thereby improving the patient's metabolic status and life quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111225680B_ABST
    Figure CN111225680B_ABST
Patent Text Reader

Abstract

The present invention provides a drug for treating non-alcoholic fatty liver disease. Specifically, the present invention provides a use of a polypeptide containing an amino acid sequence derived from hepatitis B virus (HBV) or a pharmaceutical composition thereof in the preparation of a drug for treating or preventing non-alcoholic fatty liver disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a drug for treating non-alcoholic fatty liver disease. Background Art

[0002] Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by liver histological changes similar to those of alcoholic liver disease, but without a history of excessive drinking. It is an acquired metabolic stress-induced liver injury closely related to insulin resistance and genetic susceptibility. Its pathological changes progress as the disease progresses, including simple fatty liver (SFL), non-alcoholic steatohepatitis (NASH), fatty liver fibrosis, and cirrhosis.

[0003] Insulin resistance is closely associated with non-alcoholic fatty liver disease (NAFLD). Recent studies have shown that nearly all NAFLD patients have insulin resistance in peripheral tissues and the liver, and this is not necessarily accompanied by impaired glucose tolerance or obesity. However, the severity of insulin resistance is associated with NAFLD progression. Research by international researchers has shown that insulin plays a key role in the pathogenesis of NAFLD by upregulating colony growth factor.

[0004] Lipid metabolism disorders are common in patients with nonalcoholic fatty liver disease. Studies have shown that approximately 50% of patients with lipid metabolism disorders also have fatty liver disease. The incidence of fatty liver disease in patients with severe hypertriglyceridemia and mixed hyperlipidemia is 5-6 times higher than in the general population.

[0005] Nearly all NASH patients are more than 10% overweight, and approximately one-third have type 2 diabetes. Most patients experience no obvious symptoms; some experience persistent or intermittent fatigue or malaise, and a few experience dull pain in the right upper abdomen, all of which are nonspecific. When NASH progresses to cirrhosis and liver failure, corresponding symptoms and signs may appear, making them difficult to distinguish from cirrhosis and liver failure caused by other causes.

[0006] In addition to directly leading to decompensated cirrhosis, hepatocellular carcinoma, and recurrence of transplanted livers, nonalcoholic fatty liver disease (NAFLD) can also influence the progression of other chronic liver diseases and contribute to the pathogenesis of type 2 diabetes and atherosclerosis. Metabolic syndrome-related malignancies, arteriosclerotic cardiovascular and cerebrovascular diseases, and cirrhosis are significant factors affecting the quality of life and life expectancy of patients with NAFLD. Therefore, NAFLD presents a significant medical challenge. Summary of the Invention

[0007] The present disclosure provides compositions and methods for treating non-alcoholic fatty liver disease (NAFLD) using polypeptides derived from HBV. In some embodiments, the polypeptides described herein include polypeptides derived from the pre-S1 region of any of HBV genotypes A, B, C, D, E, F, G, and H.

[0008] In some aspects, the present disclosure provides a pharmaceutical composition comprising a polypeptide described herein, wherein, when administered to a subject in need thereof, the pharmaceutical composition is capable of treating non-alcoholic fatty liver disease (NAFLD) in the subject.

[0009] In some aspects, the present disclosure provides methods for treating non-alcoholic fatty liver disease (NAFLD), comprising administering to a subject a therapeutically effective amount of a polypeptide described herein or a pharmaceutical composition containing the polypeptide.

[0010] In some embodiments, the non-alcoholic fatty liver disease (NAFLD) described herein includes simple fatty liver (SFL), non-alcoholic steatohepatitis (NASH), fatty liver fibrosis, and cirrhosis.

[0011] In some embodiments, the polypeptides described herein comprise an amino acid sequence derived from the pre-S1 region of HBV genotype A, B, C, D, E, F, G, or H. In certain embodiments, the polypeptides described herein comprise the sequence of amino acids 13-59 of the pre-S1 region of HBV genotype C. In other embodiments, the polypeptides described herein comprise a sequence corresponding to amino acids 13-59 of the pre-S1 region of HBV genotype C derived from the pre-S1 region of any other genotype of HBV. In some embodiments, the polypeptides comprise an amino acid sequence selected from any one of SEQ ID NOs: 21-40.

[0012] In some embodiments, one or more amino acid residues of the polypeptides described herein are deleted, substituted, or inserted, but the polypeptides still retain the biological activity described herein. In certain embodiments, the polypeptides described herein contain native flanking amino acid sequences from the pre-S1 region of HBV genotype A, B, C, D, E, F, G, or H. In other embodiments, the polypeptides described herein are at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any of the amino acid sequences set forth in SEQ ID NOs: 21-40. In some embodiments, the polypeptides contain a glycine corresponding to amino acid 13 of the pre-S1 region of HBV genotype C and / or an asparagine corresponding to amino acid 20 of the pre-S1 region of HBV genotype C.

[0013] In some embodiments, the polypeptides described herein contain an N-terminal hydrophobic group modification and / or a C-terminal modification that stabilizes the polypeptide. The hydrophobic group can be selected from, for example, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid. The C-terminal modification can be selected from, for example, amidation (amination), prenylation, and any C-terminal modification that stabilizes the polypeptide. In certain embodiments, the polypeptides described herein have a myristic acid modification at the N-terminus and / or an amination modification at the C-terminus. In some embodiments, the polypeptides described herein contain an amino acid sequence selected from SEQ ID NOs: 21-40. In some embodiments, the polypeptides described herein contain the amino acid sequence set forth in SEQ ID NO: 23.

[0014] In one aspect, the polypeptides described herein can reduce one or more symptoms associated with non-alcoholic fatty liver disease. In some embodiments, a polypeptide as described herein or a pharmaceutical composition comprising the polypeptide is administered before, simultaneously with, or after administration of a therapeutically effective amount of at least one second agent. The second agent can be selected from, for example, antihyperlipidemic agents, antihyperglycemic agents, antidiabetic agents, antiobesity agents, and bile acid analogs. For example, the second agent can be selected from, for example, insulin, metformin, sitagliptin, colesevelam, glipizide, simvastatin, atorvastatin, ezetimibe, fenofibrate, niacin, orlistat, lorcaserin, phentermine, topiramate, obeticholic acid, and ursodeoxycholic acid.

[0015] In some embodiments, the polypeptides described herein or pharmaceutical compositions comprising the polypeptides are administered to a subject by at least one route of administration, including, for example, parenteral, intrapulmonary, intranasal, intralesional, intramuscular, intravenous, intraarterial, intraperitoneal, and subcutaneous administration. In some embodiments, the polypeptides described herein or pharmaceutical compositions comprising the polypeptides are administered to a subject subcutaneously. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 : Comparison of liver weights in 8-week-old mice.

[0017] Figure 2 : Comparison of liver weights in 16-week-old mice.

[0018] Figure 3 : Quantitative body fat distribution by in vivo CT in 16-week-old mice.

[0019] Figure 4 : HE staining of 8-week-old mouse liver (40×200).

[0020] Figure 5 : HE staining of 16-week-old mouse liver (40×200).

[0021] Figure 6 : Oil red O staining of 8-week-old mouse liver (40×200).

[0022] Figure 7 : Oil red O staining of 16-week-old mouse liver (40×200).

[0023] Figure 8 : Masson staining of 8-week-old mouse liver (40×200).

[0024] Figure 9 : Masson staining of 16-week-old mouse liver (40×200).

[0025] Figure 10 : TUNEL staining of 8-week-old mouse liver (400×200).

[0026] Figure 11 : TUNEL staining of 16-week-old mouse liver (400×200).

[0027] Figure 12 : Semi-quantitative results of apoptosis in the liver of 8-week-old mice (40×200, 10 fields of view).

[0028] Figure 13 : Semi-quantitative results of liver cell apoptosis in 16-week-old mice (40×200, 10 fields of view).

[0029] Figure 14 : GTT test in mice at 8 weeks.

[0030] Figure 15 : GTT test in 16-week-old mice.

[0031] Figure 16 : Serum insulin levels in mice at 16 weeks.

[0032] Figure 17 : HOMA-IR in 16-week-old mice.

[0033] Figure 18 : Serum ALB and ALP levels in 16-week-old mice.

[0034] Figure 19 : Serum HDL-C and LDL-C levels in mice at 8 weeks.

[0035] Figure 20 : Serum HDL-C and LDL-C levels in 16-week-old mice.

[0036] Figure 21 : Serum VLDL levels in 16-week-old mice.

[0037] Figure 22 : Serum ALT and AST levels in mice at 8 weeks.

[0038] Figure 23 : Serum ALT and AST levels in mice at 16 weeks.

[0039] Figure 24 : Serum TG and TC levels in 8-week-old mice.

[0040] Figure 25 : Serum TG and TC levels in 16-week-old mice.

[0041] Figure 26 : TG levels in the liver of 8-week-old mice.

[0042] Figure 27 : TG levels in liver of 16-week-old mice.

[0043] Figure 28 : TC levels in the liver of 8-week-old mice.

[0044] Figure 29 : TC levels in liver of 16-week-old mice.

[0045] Figure 30 : Hydroxyproline levels in liver of 8-week-old mice.

[0046] Figure 31 : Hydroxyproline levels in liver of 16-week-old mice.

[0047] Figure 32 : FFA levels in the liver of 8-week-old mice.

[0048] Figure 33 : FFA levels in liver of 16-week-old mice. DETAILED DESCRIPTION

[0049] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a preferred technical solution.

[0050] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. For the purposes of this disclosure, the following terms are defined as follows.

[0051] The articles "a" and "an" refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "an element" refers to one element or more than one element.

[0052] Unless the context clearly indicates otherwise, the term "or" is used interchangeably with the term "and / or."

[0053] To the extent the terms "including," "comprising," "having," or their grammatical variations are used in this disclosure or the claims, these terms may be used in a manner similar to how the term "comprising" is interpreted when used as a transitional word in the claims. The term "including" or its grammatical variations means "including but not limited to," and may be used interchangeably with "including but not limited to."

[0054] The term "about" refers to an amount, level, value, numerical value, frequency, percentage, dimension, size, quantity, weight, or length that varies by approximately 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% compared to a reference amount, level, value, numerical value, frequency, percentage, dimension, size, quantity, weight, or length. When the term "about" is used in conjunction with a numerical range, the term modifies the range, extending its limits above or below the numerical value. Generally, the term "about," when modifying a numerical value, means within 10% above and below the numerical value.

[0055] I. Peptides

[0056] Certain aspects of the present disclosure provide polypeptides derived from HBV for use in treating non-alcoholic fatty liver disease in a subject. The polypeptides may be derived from the pre-S1 region of HBV. The subject may be a mammal. In some embodiments, the subject may be a human.

[0057] The terms "polypeptide", "peptide" and "protein" are used interchangeably and include full-length proteins and fragments, as well as variants of full-length proteins and fragments. These fragments and variants of the polypeptides described herein retain at least the biological activity of hepalatide. "Polypeptide", "peptide" and "protein" may include natural and / or non-natural amino acid residues. These terms also include proteins that are post-translationally modified, including, for example, glycosylated, sialylated, acetylated, and / or phosphorylated proteins. These terms also include proteins that are chemically modified at one or more amino acid residues (e.g., N-terminal and / or C-terminal amino acid residues). For example, the N-terminus of the polypeptides described herein may be modified by a hydrophobic group (e.g., myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol and arachidonic acid). In some embodiments, the C-terminus of the polypeptides described herein may be modified to stabilize the polypeptide. The C-terminal modification may be selected from amidation (amination), prenylation and any C-terminal modification that can stabilize the polypeptide.

[0058] As used herein, the terms "polypeptide derived from HBV" or "HBV-derived polypeptide" refer to polypeptides whose origin or source is HBV and may include native, recombinant, synthetic, or purified polypeptides. The terms "polypeptide derived from HBV" or "HBV-derived polypeptide" refer to full-length native HBV polypeptides or fragments thereof, as well as variants of full-length native polypeptides or fragments thereof. In some embodiments, a fragment may consist of at least 3-5 amino acids, at least 5-10 amino acids, at least 10-20 amino acids, at least 20-30 amino acids, at least 30-50 amino acids, or all amino acids of a native sequence, or may be identified by one of ordinary skill in the art as being derived from such a native sequence. In some embodiments, the polypeptides described herein may be derived from the pre-S1 region of any HBV subtype L protein. In some embodiments, the polypeptides described herein may contain the entire pre-S1 region of any HBV subtype L protein. In certain embodiments, the polypeptides described herein may be derived from the pre-S1 region of any of the HBV genotypes A, B, C, D, E, F, G, and H L proteins. The genomic sequences of these HBV genotypes can be found in GenBank Accession Nos. KC875260 (SEQ ID NO: 41), AY220704 (SEQ ID NO: 42), AF461363 (SEQ ID NO: 43), AY796030 (SEQ ID NO: 44), AB205129 (SEQ ID NO: 45), DQ823095 (SEQ ID NO: 46), HE981176 (SEQ ID NO: 47), and AB179747 (SEQ ID NO: 48), respectively. In certain embodiments, the polypeptides described herein can be derived from the pre-S1 region of the L protein of HBV genotype C. The HBV-derived polypeptides described herein retain one or more of the biological activities described herein of the corresponding native HBV polypeptides.

[0059] As used herein, a "variant" related to a polypeptide described herein, a polypeptide derived from HBV, or an HBV-derived polypeptide refers to a polypeptide that differs from a given polypeptide (i.e., a polypeptide described herein, a polypeptide derived from HBV, or an HBV-derived polypeptide) in amino acid sequence but retains one or more biological activities described herein of the given polypeptide. The variant polypeptides described herein may have one or more amino acid additions (e.g., insertions), deletions, or substitutions relative to a given polypeptide. In some embodiments, the variant polypeptides described herein may have 1-30, 1-20, 1-10, 1-8, 1-5, or 1-3 (including all integers within these ranges) amino acid additions (e.g., insertions), deletions, or substitutions relative to a given polypeptide. For example, a polypeptide sequence may contain conservative substitutions of amino acids. Conservative substitutions of amino acids, i.e., replacing an amino acid with a different amino acid having similar properties (e.g., hydrophilicity and charge level and distribution of charged regions), generally involve minor changes and therefore do not significantly alter the biological activity of the polypeptide. These minor changes can be identified, in part, by considering the hydropathic index of the amino acid based on the hydrophobicity and charge of the amino acid. Amino acids with similar hydropathic index and hydrophilicity values ​​can be substituted for each other and still retain protein function. The hydropathic index and hydrophilicity values ​​of an amino acid are influenced by the specific side chain of that amino acid. Consistent with this observation, amino acid substitutions that match biological function depend on the relative similarity of the amino acids, particularly those of their side chains, as expressed in terms of hydrophobicity, hydrophilicity, charge, size, and other properties.

[0060] The term "variant" also includes polypeptides having a certain degree of identity with a given polypeptide, such as at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with a given polypeptide. As used herein, "variant" also includes polypeptides that contain a portion of a given polypeptide corresponding to the native sequence of an HBV protein. "Variant" may also refer to a fusion protein or chimeric protein, a polypeptide containing proteins derived from two or more different sources. Non-limiting examples of fusion proteins described herein may include, for example, a fusion protein of a polypeptide derived from HBV and another polypeptide derived from a non-HBV protein, a fusion protein of two polypeptides derived from different HBV subtypes, and a fusion protein of two polypeptides derived from different regions of the L protein of any HBV subtype or two polypeptides derived from different sequences within the pre-S1 region of the L protein of any HBV subtype.

[0061] The term "variant" also includes polypeptides that contain the same amino acid sequence as a given polypeptide (i.e., a polypeptide described herein, a polypeptide derived from HBV, or an HBV-derived polypeptide), retain one or more biological activities of the given polypeptide, but have been chemically and / or post-translationally modified in a manner different from that of the given polypeptide. "Variant" can also be used to describe polypeptides that have been differentially processed, such as by proteolysis, phosphorylation, or other post-translational modifications, but retain the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated bile acid transport to hepatocytes. Herein, unless otherwise indicated, "variant" includes fragments of variants. The term "variant" also includes homologous polypeptide sequences found in different viral species, strains, or hepadnavirus subtypes. HBV is divided into four major serotypes (adr, adw, ayr, and ayw) based on antigenic epitopes on its envelope protein, and HBV is divided into eight genotypes (AH) based on the variability of the entire nucleotide sequence in the genome. Therefore, the term "variant" includes any of these homologous polypeptides found in HBV subtypes. "Variants" may also include polypeptides with native flanking amino acid sequences from any of these HBV subtypes added to the N- and / or C-termini.

[0062] The terms "conservative amino acid substitution" and "conservative substitution" are used interchangeably herein to refer to a specified amino acid exchange within a group of amino acids, wherein an amino acid is exchanged for a different amino acid of similar size, structure, charge, and / or polarity. Families of amino acid residues with similar side chains are well known in the art and include basic side chains (e.g., leucine, arginine, and histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, in some embodiments, an amino acid residue in a polypeptide can be replaced with another amino acid residue from the same side chain family. In other embodiments, an amino acid sequence can be replaced with an amino acid sequence that is structurally similar but differs in the order and / or composition of the side chain family members. In other embodiments, mutations can be randomly introduced into the entire sequence or a portion of the polypeptide. Examples of conservative amino acid substitutions include, for example, replacing one of the aliphatic or hydrophobic amino acids Ala, Val, Leu, and Ile with another amino acid in the group of four amino acids; substitutions between hydroxyl-containing residues Ser and Thr; substitutions between acidic residues Asp and Glu; substitutions between amide residues Asn and Gln; substitutions between basic residues Lys, Arg, and His; substitutions between aromatic residues Phe, Tyr, and Trp; and substitutions between small amino acids Ala, Ser, Thr, Met, and Gly. It is reasonably expected that conservative substitutions, such as replacing a conservative amino acid with a similar, structurally related amino acid, will not have a substantial effect on the biological activity of the polypeptide.

[0063] The term "sequence identity" (e.g., 50% identity to a sequence) refers to the degree to which sequences are identical when compared amino acid to amino acid over a comparison window. In some embodiments, the polypeptides described herein may contain an amino acid sequence that is at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequence of a given polypeptide and still retains one or more biological activities of the given polypeptide. "Percent identity" or "% identity" can be calculated by optimally aligning the two sequences over a comparison window, determining the number of positions at which the identical amino acid appears in the two sequences to obtain the number of matching positions, and dividing the number of matching positions by the total number of positions in the comparison window, and multiplying the result by 100 to obtain the percentage of sequence identity. Optimal sequence alignment for alignment over a comparison window can be performed by using a computer to execute algorithms known in the art, such as The program of the family, or by visual observation, adopts any method selected to produce the best arrangement (that is, to produce the highest homology percentage in the comparison window). For sequence comparison, a sequence is used as a reference sequence, and the test sequence is compared with the reference sequence. When using a sequence comparison algorithm, the test and reference sequences are input into a computer, and if necessary, subsequence coordinates can be designed and sequence algorithm program parameters are set. Then, the sequence comparison algorithm calculates the current sequence identity of the test sequence relative to the reference sequence based on the set program parameters. The setting of sequence algorithm program parameters is well known in the art. For example, the comparison window can be set to cover the entire length of any one or two comparison sequences, such as covering the entire length of the reference sequence, while allowing the presence of a difference of up to 5% of the total amino acid number of the reference sequence.

[0064] As used herein, the "biological activity" of the polypeptides described herein includes the biological activity of the polypeptide in reducing subcutaneous fat, liver fat, and serum fat deposition in a subject (e.g., a C57BL6 mouse), reducing serum ALT and AST levels, improving the degree of apoptosis, and alleviating the degree of liver fibrosis. In certain aspects, the "biological activity" also includes increasing the total bile acid (TBA) level in the subject, and reducing serum albumin (ALB), HDL, and LDL levels. In certain aspects, the "biological activity" also includes reducing blood glucose and insulin levels in the subject, and improving insulin resistance.

[0065] In certain embodiments, the "biological activity" of a polypeptide as described herein includes the ability of the polypeptide to improve or prevent one or more symptoms or complications of the disease. In certain embodiments, the "biological activity" of a polypeptide as described herein includes the ability of the polypeptide to alleviate the negative effects of these diseases on the patient's health or reduce the risk of developing these diseases. In certain embodiments, the "biological activity" of a polypeptide as described herein also includes the ability of the polypeptide to reduce the severity of other related diseases (such as atherosclerosis and / or cardiovascular disease, heart disease, kidney damage, or obesity) or reduce the risk of developing other related diseases.

[0066] The present disclosure includes various in vivo, in vitro and ex vivo detection methods for determining the biological activity of the polypeptides described herein. The in vivo biological activity of the polypeptides described herein can be determined by collecting samples from subjects treated with the polypeptides. The sample can be a biopsy sample collected from a specific tissue such as liver, muscle, fat and pancreas, or a quick-frozen tissue obtained by autopsy of an animal. In some embodiments, the sample can be a serum sample collected from the blood of the subject. Various methods for collecting serum samples from subjects are well known in the art, including tail bleeding, retro-orbital puncture and cardiac puncture. In certain embodiments, the biological activity of the polypeptides described herein can be determined in vitro by contacting the polypeptides described herein with a cell, which can be a transformed cell line or a cell isolated from an animal. In some embodiments, the cell can be a primary hepatocyte isolated from an animal.

[0067] Exemplary assays for determining the biological activity of the polypeptides described herein may also include functional assays performed using samples collected from subjects treated with the polypeptides described herein, including, for example, glucose production assays, glucose uptake assays, fatty acid oxidation assays, cholesterol assays, bile acid assays, urea assays, and triglyceride assays.

[0068] In some embodiments, the polypeptides described herein may contain an amino acid sequence from the pre-S1 region of any HBV subtype. In some embodiments, the polypeptides described herein contain amino acids 13-59 of the pre-S1 region of HBV genotype C: GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEANQVG (SEQ ID NO: 23). In other embodiments, the polypeptides described herein may contain a corresponding pre-S1 sequence from another HBV genotype (e.g., from any of genotypes A, B, C, D, E, F, G, and H). For example, in certain embodiments, the polypeptides described herein may contain:

[0069] HBV genotype A pre-S1 amino acids 13-59:

[0070]

[0071] HBV genotype B pre-S1 amino acids 13-59:

[0072]

[0073] HBV genotype D pre-S1 amino acids 2-48:

[0074]

[0075] HBV genotype E pre-S1 amino acids 12-58:

[0076]

[0077] HBV genotype F pre-S1 amino acids 13-59:

[0078]

[0079] HBV genotype G pre-S1 amino acids 12-58:

[0080] GKNLSASNPLGFLPDHQLDPAFRANTNNPDWDFNPKKDPWPEANKVG (SEQ ID NO: 39); or

[0081] HBV genotype H pre-S1 amino acids 13-59:

[0082]

[0083] In some embodiments, the polypeptides described herein may contain a portion of the pre-S1 region of HBV, said portion containing at least one amino acid sequence selected from SEQ ID NOs: 23 and 34-40. In some embodiments, the polypeptides described herein may contain the entire pre-S1 region of HBV.

[0084] In some embodiments, the polypeptide described herein can be 10-100 amino acids in length. For example, the polypeptide can be 15-100, 15-80, 20-100, 20-80, 20-60, 25-60, 30-60, 35-60 or 40-60 (including all integers between these ranges) amino acids in length. In some embodiments, the polypeptide described herein can be at least 20 amino acids in length, for example, at least 25, 30, 35 or 40 amino acids in length. In some embodiments, the polypeptide described herein can be 20, 25, 30, 35, 40, 47, 55 or 60 amino acids in length. In some embodiments, the polypeptide described herein can be 47 amino acids in length. Variants of different lengths of polypeptides described herein retain one or more biological activities associated with the corresponding polypeptides.

[0085] In some embodiments, the N-terminus of the polypeptides described herein may be modified with a hydrophobic group. For example, the hydrophobic group may be selected from the group consisting of myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid. In some embodiments, the hydrophobic group may be selected from the group consisting of myristic acid, palmitic acid, stearic acid, and cholesterol. In some embodiments, the hydrophobic group may be myristic acid. In certain embodiments, the polypeptides described herein may comprise an amino acid sequence selected from any one of SEQ ID NOs: 23 and 34-40, wherein the N-terminus of the polypeptide may be modified with a hydrophobic group selected from the group consisting of myristic acid, palmitic acid, stearic acid, and cholesterol. In certain embodiments, the polypeptides described herein may comprise an amino acid sequence selected from any one of SEQ ID NOs: 23 and 34-40, wherein the N-terminus of the polypeptide may be myristoylated. In some embodiments, the polypeptides described herein may comprise an amino acid sequence selected from any one of SEQ ID NOs: 23 and 34-40, wherein the N-terminus of the polypeptide may be myristoylated. In some embodiments, the polypeptides described herein may comprise a C-terminal modification to stabilize the polypeptide. For example, the C-terminal modification can be selected from amidation (amination), prenylation, and any C-terminal modification that stabilizes the polypeptides described herein. In some embodiments, the C-terminal modification can be amidation (amination). For example, the polypeptide described herein can comprise the amino acid sequence set forth in SEQ ID NO: 23, wherein the N-terminus can be myristoylated and / or the C-terminus can be amidated (aminated). In some embodiments, the polypeptide described herein can comprise the amino acid sequence set forth in SEQ ID NO: 23 (Cmyr-47). In some embodiments, the polypeptide described herein can comprise an amino acid sequence selected from any one of SEQ ID NOs: 34-40, wherein the N-terminus of the polypeptide can be myristoylated and / or the C-terminus can be amidated (aminated). In some embodiments, the polypeptide described herein can comprise an amino acid sequence selected from any one of SEQ ID NOs: 14-20. Variants of the polypeptides described herein that are modified at the N-terminus and / or C-terminus retain one or more biological activities of the corresponding polypeptides that are not modified in the same manner, including at least the biological activity of binding to NTCP and bidirectionally regulating NTCP-mediated bile acid transport to hepatocytes.

[0086] Variants of the polypeptides described herein are also included in the present disclosure, including those having one or more amino acid deletions, substitutions or insertions while retaining one or more biological activities of the polypeptide. The polypeptides described herein preferably retain the glycine corresponding to amino acid 13 of the pre-S1 region of HBV genotype C (i.e., the N-terminal glycine of SEQ ID NO: 23). In some embodiments, the polypeptides described herein retain the asparagine corresponding to amino acid 20 of the pre-S1 region of HBV genotype C. In some embodiments, the polypeptides described herein may have one or more naturally occurring mutations in the pre-S1 region of HBV. In some embodiments, the polypeptides described herein may have 1-30, e.g., 1-20, 1-10, 1-8, 1-5, or 1-3 (including all integers within these ranges) amino acid deletions, substitutions, or insertions relative to the sequence from the pre-S1 region of HBV. In some embodiments, the polypeptides described herein may have 1-30, such as 1-20, 1-10, 1-8, 1-5, or 1-3 (including all integers within these ranges) amino acid deletions, substitutions, or insertions relative to the amino acid sequence set forth in any one of SEQ ID NOs: 23 and 34-40. In some embodiments, the polypeptides described herein have 1-30, such as 1-20, 1-10, 1-8, 1-5, or 1-3 (including all integers within these ranges) amino acid deletions, substitutions, or insertions relative to the amino acid sequence of SEQ ID NO: 23. In some embodiments, the polypeptides described herein have 1-3 amino acid deletions, substitutions, or insertions relative to the amino acid sequence of SEQ ID NO: 23. In certain embodiments, the polypeptides described herein have 1-30, such as 1-20, 1-10, 1-8, 1-5, or 1-3 (including all integers within these ranges) amino acid deletions or insertions at the C-terminus relative to the amino acid sequence set forth in any one of SEQ ID NOs: 23 and 34-40. For example, the polypeptide described herein may comprise an amino acid sequence selected from any one of SEQ ID NOs: 21, 22, and 24-28. In some embodiments, the polypeptide described herein may comprise an amino acid sequence of any one of the polypeptides listed in Table 1. In some embodiments, the polypeptide described herein may be selected from any one of the post-translationally modified polypeptides listed in Table 1.

[0087] Table 1: List of exemplary polypeptides

[0088]

[0089]

[0090] In various embodiments, the polypeptides described herein can be at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any of the polypeptides described herein. For example, the polypeptide can comprise an amino acid sequence that is at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 21-40. In some embodiments, the polypeptide can comprise an amino acid sequence that is at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any of SEQ ID NOs: 23 and 34-40. In some embodiments, the polypeptide may comprise an amino acid sequence that is at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 23. Variants having a certain sequence identity to the polypeptides described herein retain one or more biological activities of the corresponding polypeptide.

[0091] Aspects of the present disclosure also include variants of the polypeptides described herein having native flanking amino acid sequences from the HBV L protein (e.g., from the pre-S1 region of the L protein) at the N- and / or C-termini of the variants. The native flanking amino acid sequences refer to native sequences that flank the N- or C-termini of the polypeptides described herein within the pre-S1 region of the corresponding HBV genotype or any other HBV genotype. In some embodiments, the polypeptides described herein may contain an amino acid sequence selected from the group consisting of SEQ ID NOs: 23 and 34-40, as well as native amino acid sequences flanking the N- and / or C-termini derived from the pre-S1 region of any of HBV genotypes A and H. In some embodiments, the native flanking amino acid sequence can be derived from the consensus sequence of HBV strains with GenBank accession numbers KC875260 (genotype A; SEQ ID NO: 41), AY220704 (genotype B; SEQ ID NO: 42), AF461363 (genotype C; SEQ ID NO: 43), AY796030 (genotype D; SEQ ID NO: 44), AB205129 (genotype E; SEQ ID NO: 45), DQ823095 (genotype F; SEQ ID NO: 46), HE981176 (genotype G; SEQ ID NO: 47), or AB179747 (genotype H; SEQ ID NO: 48). For example, a polypeptide described herein can comprise the amino acid sequence set forth in SEQ ID NO: 23 and contain native flanking amino acid sequences from the pre-S1 region of HBV genotype C at its N- and / or C-terminus. Alternatively, the polypeptide described herein may comprise the amino acid sequence set forth in SEQ ID NO: 23 and, at its N- and / or C-terminus, a naturally occurring flanking amino acid sequence from the pre-S1 region of any of HBV genotypes A, B, D, E, F, G, and H. In some embodiments, the N- and / or C-terminus of the polypeptide described herein may independently comprise a naturally occurring flanking amino acid sequence of 1-10 amino acids, such as 1-8, 1-5, or 1-3 amino acids (including all integers within these ranges). For example, the polypeptide described herein may comprise the amino acid sequence set forth in SEQ ID NO: 23 and, at its N-terminus, a naturally occurring flanking amino acid sequence of 10 amino acids from the pre-S1 region of HBV genotype C. In other words, the polypeptide may comprise amino acids 2-59 of the pre-S1 region of HBV genotype C (SEQ ID NO: 29). As another example, the polypeptide described herein may comprise the amino acid sequence set forth in SEQ ID NO: 23 and, at its N-terminus, a naturally occurring flanking amino acid sequence of 9 amino acids from the pre-S1 region of HBV genotypes E or G.In other words, the polypeptide may contain amino acids 13-59 of the pre-S1 region of HBV genotype C and amino acids 2-11 of the pre-S1 region of HBV genotype E or G (SEQ ID NO: 30). It should be understood that any of the polypeptides described herein may have any length of native flanking amino acid sequence extending from its N- and / or C-terminus, and the resulting polypeptide retains one or more biological activities of the original polypeptide.

[0092] As used herein, "modulate" or "alter" are used interchangeably and include "lowering," "decreasing," "decreasing," "downregulating," or "inhibiting" one or more quantifiable parameters, optionally by a certain amount and / or a statistically significant amount. The term "modulate" also includes "increasing," "increasing," "elevating," "upregulating," or "promoting" one or more quantifiable parameters, optionally by a certain amount and / or a statistically significant amount.

[0093] The terms "reduce," "decrease," "decrease," "downregulate," or "inhibit" are used interchangeably herein and refer to a decrease in the level or activity of one or more chemical or biological molecules associated with metabolism below the level or activity observed in the absence of a polypeptide described herein, or below the level or activity produced by a control polypeptide. In some embodiments, "reduction" may refer to a decrease in the level or value of one or more physiological parameters that measure changes in metabolism, such as body weight, fat mass, and homeostasis model assessment (HOMA) index, below the level or activity observed in the absence of a polypeptide described herein, or below the level or activity produced by a control polypeptide. In certain embodiments, the decrease in production of a polypeptide described herein is below the level or activity observed in the presence of an inactive or attenuated molecule.

[0094] As used herein, the homeostasis model assessment (HOMA) index may refer to the HOMA-IR (quantitative insulin resistance) index. The HOMA-IR value can be calculated using the following formula: HOMA-IR = [(blood glucose in mmol / L) x (serum insulin in mU / L)] / 22.5.

[0095] Likewise, the terms "enhance," "increase," "elevate," "upregulate," and "promote" are used interchangeably to refer to an increase in the level or activity of one or more chemical or biological molecules associated with metabolism above that observed in the absence of a polypeptide described herein, or above that produced by a control polypeptide. In some embodiments, "enhancement" may refer to an increase in the value of one or more physiological parameters that measure changes in metabolism, such as body weight, fat mass, and homeostasis model assessment (HOMA) index, above that observed in the absence of a polypeptide described herein, or above that produced by a control polypeptide. In certain embodiments, the increase produced by a polypeptide described herein is above that observed in the presence of an inactive or attenuated molecule.

[0096] The terms "stable," "retain," "maintain," and "maintain" are used interchangeably with respect to one or more chemical or biological molecules associated with metabolism, and refer to levels or activities of the one or more chemical or biological molecules associated with metabolism that show minimal difference compared to the levels or activities observed in healthy subjects or subjects without metabolic diseases, or compared to the levels or activities observed in the presence of a positive control polypeptide. In some embodiments, "stable" may refer to levels or values ​​of one or more physiological parameters that measure metabolic changes, such as body weight, fat mass, and the homeostasis model assessment (HOMA) index, that show minimal difference compared to the levels or values ​​observed in healthy subjects or subjects without metabolic diseases, or compared to the levels or values ​​observed in the presence of a positive control polypeptide.

[0097] The polypeptides described herein can be prepared by chemical synthesis or recombinant technology.

[0098] When recombinant methods are chosen, a synthetic gene can be constructed de novo, or a natural gene can be mutated using, for example, cassette mutagenesis. The polypeptides described herein can be prepared using recombinant DNA techniques. Briefly, these techniques involve obtaining a natural or synthetic gene encoding the polypeptide, inserting it into a suitable vector, transferring the vector into a suitable host cell, culturing the host cell to express the gene, and recovering or isolating the produced peptide. In some embodiments, the recovered peptide is purified to a suitable purity.

[0099] For example, clone and manipulate the DNA sequence encoding the polypeptide described herein so that it can be expressed in a suitable host. DNA encoding the parent polypeptide can be obtained from the cDNA of the mRNA of the cell expressing the polypeptide in the HBV genomic library, or the DNA sequence encoding the parent polypeptide can be constructed using a synthetic method. The parent DNA is then inserted into a suitable plasmid or vector for transforming the host cell. Typically, plasmid vectors derived from species compatible with the host cell and containing replication and control sequences are used in these hosts. Vectors typically carry replication sites and coding sequences that can provide proteins or peptides for phenotypic selection for the transformed cells. Vectors can be those commonly used in this area, or constructed using standard techniques and in conjunction with the functional fragments of commonly used vectors in this area.

[0100] The host cell can be a prokaryotic cell or a eukaryotic cell. For example, prokaryotic host cells can include Escherichia coli, Bacillus subtilis and other Enterobacteriaceae such as Salmonella typhimurium or Serratia marcesans, and various Pseudomonas. Except prokaryotes, eukaryotes can also be used, such as yeast cultures, or cells derived from multicellular organisms, such as insect or mammalian cell cultures. The example of this type of eukaryotic host cell line includes VERO and Hela cells, Chinese hamster ovary (CHO) cell line, W138, 293, BHK, COS-7 and MDCK cell line.

[0101] In some embodiments, the polypeptides described herein can be prepared using solid-phase synthesis or equivalent chemical synthesis methods known in the art. In some embodiments, solid-phase synthesis of the C-terminus of the polypeptide is initiated by coupling a pre-protected α-amino acid to a suitable resin. The starting material can be prepared by linking an α-amino-protected amino acid to a chloromethylated resin or a hydroxymethylated resin via an ester bond, or to a BHA resin or MBHA resin via an amide bond. The amino acid is linked to the peptide chain using techniques well known in the art for forming peptide bonds. One method involves converting the amino acid into a derivative that provides a carboxyl group that is more readily reactive with the free N-terminal amino group of the peptide fragment. For example, the amino acid can be converted into a mixed anhydride by reacting the protected amino acid with ethyl chloroformate, phenyl chloroformate, tert-butyl chloroformate, isobutyl chloroformate, pivaloyl chloride, or a similar acid chloride. Alternatively, the amino acid can be converted into an active ester, such as 2,4,5-trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, p-nitrophenyl ester, N-hydroxysuccinimide ester, or an ester formed from 1-hydroxybenzotriazole. Another coupling method involves the use of a suitable coupling agent, such as N,N'-dicyclohexylcarbodiimide or N,N'-diisopropylcarbodiimide.

[0102] In some embodiments, the alpha-amino groups of the amino acids used in peptide synthesis are protected during the coupling reaction to prevent side reactions involving their active alpha-amino functions. For example, certain amino acids containing reactive side chain functional groups (e.g., sulfhydryl, amino, carboxyl, and hydroxyl groups) can be protected with suitable protecting groups to prevent chemical reactions at these sites during the initial and subsequent coupling steps. Those skilled in the art will appreciate the selection of appropriate side chain protecting groups. After obtaining a peptide of the desired amino acid, the protecting groups can be readily removed under reaction conditions that do not alter the peptide chain structure.

[0103] After removing the α-amino protecting group, the remaining α-amino groups and side-chain protected amino acids are coupled stepwise in the desired order. In addition to adding each amino acid individually during the synthesis, as an alternative, some amino acids can be coupled to each other before being added to the solid phase synthesizer. Those skilled in the art are familiar with how to select an appropriate coupling agent.

[0104] Each protected amino acid or amino acid sequence is added in excess to a solid phase reactor, and the coupling is preferably carried out in a medium of dimethylformamide (DMF) or CH2Cl2 or a mixture thereof. If the coupling is incomplete, the coupling process is repeated in the presence of an N-amino protecting group before coupling the next amino acid. The success of the coupling reaction at each stage of the synthesis can be monitored. Well-known methods such as BIOSEARCH 9500 can be used. TM The coupling reaction was performed automatically by a peptide synthesizer.

[0105] After obtaining the desired peptide sequence, the protected peptide must be cut from the resin support and all protecting groups must be removed. The cutting and removal of the protecting groups can be carried out simultaneously or sequentially. When the resin support is a chloromethylated polystyrene resin, the bond anchoring the peptide to the resin is an ester bond formed between the free carboxyl group of the C-terminal residue and one of the numerous chloromethyl groups on the resin matrix. It should be understood that the bond for anchoring can be cut using reagents known to break ester bonds and to penetrate the resin matrix. It should also be recognized that the polypeptide can be modified before or after cutting the polypeptide from the support, such as modifying the N-terminus with a hydrophobic group (including, for example, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol, and arachidonic acid), or modifying the C-terminus with amidation (amination), prenylation, or other modifications that stabilize the C-terminus.

[0106] The polypeptides of the present invention can be purified by conventional methods such as preparative HPLC (including reverse phase HPLC) or other known chromatographic techniques (such as gel permeation, ion exchange, partition chromatography, affinity chromatography (including monoclonal antibody columns) or countercurrent distribution).

[0107] II. Pharmaceutical Composition

[0108] The present disclosure also provides compositions, including pharmaceutical compositions, comprising the polypeptides described herein. In certain embodiments, the compositions may comprise any one or more polypeptides described herein. In some embodiments, the compositions may further comprise a suitable pharmaceutically acceptable carrier.

[0109] A "pharmaceutically acceptable carrier" refers to an inactive ingredient, such as a solid, semisolid, or liquid filler, diluent, coating material, formulation adjuvant, excipient, or vehicle, that is combined with the therapeutic agent to form a "pharmaceutical composition" for administration to a subject. A pharmaceutically acceptable carrier is nontoxic to the subject at the dosage and concentration used and is compatible with the other ingredients in the formulation. A pharmaceutically acceptable carrier is appropriate for the formulation being employed. For example, if the therapeutic agent is to be administered orally, the carrier can be a gel capsule. If the therapeutic agent is to be administered subcutaneously, it is ideal that the carrier is non-irritating to the skin and does not cause injection site reactions.

[0110] The polypeptides described herein having the desired purity can be mixed with one or more optional pharmaceutically acceptable carriers to prepare pharmaceutical compositions of the polypeptides. Pharmaceutically acceptable carriers may include, for example, buffers (such as phosphates, citrates, and other organic acids); antioxidants (such as ascorbic acid and methionine); preservatives (such as octadecylbenzyldimethylammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcohol or benzyl alcohol, alkyl parabens such as methyl paraben or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol); low molecular weight (such as less than about 10 residues) polypeptides; proteins (such as serum albumin, gelatin or immunoglobulin); hydrophilic polymers (such as polyvinylpyrrolidone); amino acids (such as glycine, glutamine, asparagine, histidine, arginine or lysine); monosaccharides; disaccharides; and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions, such as sodium; metal complexes, such as Zn-protein complexes; and / or nonionic surfactants, such as polyethylene glycol (PEG).

[0111] Exemplary pharmaceutical carriers may also include binders, such as pregelatinized corn starch, polyvinyl pyrrolidone or hydroxypropyl methylcellulose; fillers, such as lactose or other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylate or calcium hydrogen phosphate; lubricants, such as magnesium stearate, talc, silicon dioxide, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycol, sodium benzoate, sodium acetate, etc.; disintegrants, such as starch, sodium starch glycolate, etc.; and wetting agents, such as sodium lauryl sulfate, etc.

[0112] Exemplary pharmaceutically acceptable carriers may also include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoprotein (sHASEGP), such as human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 ( Baxter International, Inc.) In some embodiments, sHASEGP can be mixed into a pharmaceutical composition containing one or more other glycosammoglycanases, such as chondroitinase.

[0113] The pharmaceutical composition may also contain more than one active ingredient suitable for the specific indication being treated, such active agents may be, for example, active agents with complementary activities that do not adversely affect each other. Such active agents may be suitably present in combination in amounts effective to achieve the intended purpose.

[0114] In some embodiments, the active agent can be encapsulated in microcapsules prepared by, for example, coacervation techniques or interfacial polymerization (e.g., hydroxymethyl cellulose or gelatin microcapsules or polymethyl methacrylate microcapsules), or in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules), or in macroemulsions.

[0115] In some embodiments, the pharmaceutical composition may include a sustained-release preparation. Suitable examples of sustained-release preparations include, for example, semipermeable matrices of solid hydrophobic polymers containing the polypeptide described herein, which matrices can be in the form of shaped articles, such as films or microcapsules.

[0116] In some embodiments, the pharmaceutical compositions are suitable for in vivo administration and can be sterile. Sterility can be readily achieved, for example, by filtration through sterile filtration membranes.

[0117] The pharmaceutical composition can be prepared into any of a variety of possible dosage forms, such as tablets, capsules, gel capsules, powders or granules. The pharmaceutical composition can also be prepared into a solution, suspension, emulsion or mixed medium. In some embodiments, the pharmaceutical composition can be prepared into a lyophilized formulation or an aqueous solution.

[0118] In some embodiments, the pharmaceutical composition can be prepared as a solution. For example, the polypeptides described herein can be added to a non-buffered solution (such as saline or water) for administration. In some embodiments, the polypeptides can also be added to a suitable buffered solution for administration. For example, the buffered solution can contain acetate, citrate, prolamin, carbonate or phosphate, or any combination thereof. In some embodiments, the buffered solution can be phosphate buffered saline (PBS). The pH and osmotic pressure of the buffered solution containing the polypeptide can be adjusted to a level suitable for administration to a subject.

[0119] In some embodiments, the pharmaceutical composition can be prepared as an aqueous suspension, a non-aqueous suspension, or a mixed matrix suspension. The aqueous suspension may also contain substances that increase the viscosity of the suspension, including, for example, sodium carboxymethylcellulose, sorbitol, and / or dextran. The suspension may also contain a stabilizer.

[0120] In some embodiments, the pharmaceutical composition can be prepared as an emulsion. Exemplary emulsions include heterogeneous systems formed by dispersing one liquid in another liquid as droplets, typically exceeding 0.1 μm in diameter. In addition to the dispersed phase and the active drug, which may be present in an aqueous solution, an oily solution, or as a separate phase, the emulsion may contain other ingredients. Microemulsions may also be included as an embodiment of the present disclosure. In some embodiments, the pharmaceutical composition may also be prepared as a liposomal formulation.

[0121] III. Usage

[0122] Embodiments of the present disclosure include therapeutic and pharmaceutical uses of the polypeptides described herein. Thus, in one aspect, the use of the polypeptides described herein as a medicament or in the preparation of a medicament is provided. In another aspect, the use of the polypeptides described herein for treating non-alcoholic fatty liver disease is provided. Also provided are methods of treating non-alcoholic fatty liver disease in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide described herein or a pharmaceutical composition of the polypeptide. In certain embodiments, the methods and uses described herein may further comprise administering to the subject a therapeutically effective amount of at least one other therapeutic agent.

[0123] The non-alcoholic fatty liver disease described herein includes, but is not limited to, simple fatty liver (SFL), non-alcoholic steatohepatitis (NASH), fatty liver fibrosis and cirrhosis, and particularly includes NASH.

[0124] As used herein, "patient" and "subject" are used interchangeably to refer to an animal (e.g., a mammal or a human) to be treated or evaluated for a disease, disorder, or condition, or to be evaluated for risk of developing a disease, disorder, or condition, or to an animal (e.g., a mammal) or a human who has developed a disease, disorder, or condition. In some embodiments, these diseases, disorders, or conditions may include non-alcoholic fatty liver disease as described herein.

[0125] A "therapeutically effective amount" or "effective amount" of a polypeptide or a composition comprising the polypeptide as described herein refers to an amount of the polypeptide or composition that is effective for the prevention or treatment of a disease. The "therapeutically effective amount" or "effective amount" may vary depending on the polypeptide, the route of administration, the disease and its severity, health, age, weight, family history, genetic makeup, stage of disease progression, types of prior and concurrent treatments, and other individual characteristics of the subject to be treated.

[0126] In various embodiments, the term "treatment" includes processing an object (such as a mammal, such as a human) or a cell to change the current process of the object or cell. Treatment includes, for example, administering a polypeptide as described herein or a pharmaceutical composition containing the polypeptide, and treatment can be carried out in a preventive manner, or can be started after a pathological event has occurred or after contact with a pathogenic substance. Treatment also includes "preventive" treatment, which is directed to reducing the rate of progression of the disease or condition to be treated, delaying the onset of the disease or condition, or reducing the severity of its onset. "Treatment" or "prevention" does not necessarily mean complete eradication, cure, or prevention of the occurrence of a disease or condition or related symptoms. In some embodiments, the term "treatment" may include improving at least one symptom or at least one measurable parameter of non-alcoholic fatty liver disease. It is obvious to those skilled in the art that biological and / or physiological parameters can be used to assess the pathological process of metabolic diseases. These pathological processes or symptoms may include, for example, excess or increased levels of one or more metabolic-related chemical or biological molecules, such as glucose, triglycerides, cholesterol, free fatty acids, bile acids, amino acids, hormones (including insulin), LDL-C, HDL-C, HbA1c, blood urea nitrogen, and minerals, compared to healthy subjects, or excess or increased levels of one or more physiological parameters that measure metabolic changes, such as blood glucose, blood pressure, body weight, fat mass, body mass index (BMI), inflammation, atherosclerosis index (AI), cardiac index, renal index, total fat index, and homeostasis model assessment (HOMA) index.

[0127] The terms "administering" or "administering" include administering a polypeptide as described herein in a local or systemic manner. Administration can be topical (including ocular or vaginal and rectal mucosal administration), pulmonary (e.g., by inhalation or insufflation of a powder or aerosol, including use of a nebulizer, intratracheal, intranasal), epidermal, transdermal, oral, or parenteral. Parenteral administration includes intravenous, subcutaneous, intraperitoneal, or intramuscular injection or infusion, or intracranial, such as intrathecal or intraventricular administration.

[0128] In a further aspect, the present disclosure provides a use of the polypeptide described herein in the preparation or manufacture of a medicament. In some embodiments, the medicament can be used to treat non-alcoholic fatty liver disease as described herein.

[0129] In certain embodiments, the methods and uses described herein may further comprise administering to a subject an effective amount of at least one other therapeutic agent. In certain embodiments, the other therapeutic agent may be used to prevent and / or treat one or more diseases associated with the non-alcoholic fatty liver disease described herein, such as one or more diseases associated with diabetes or hyperlipidemia. In certain embodiments, the other therapeutic agent may be used to prevent and / or treat cardiovascular disease, such as atherosclerotic disease. In certain embodiments, the other therapeutic agent may be used to reduce the risk of recurrent cardiovascular events. In certain embodiments, the other therapeutic agent may be used to prevent and / or treat heart disease, kidney damage or obesity. The polypeptides described herein may be used alone or in combination with other formulations. For example, any one of the polypeptides described herein may be administered before, simultaneously with, or after administration of the other therapeutic agent. In certain embodiments, the other therapeutic agent may be selected from, for example, lipid-lowering drugs, glucose-lowering drugs, antidiabetic drugs, antiobesity drugs, and bile acid analogs.

[0130] In some embodiments, the glucose-lowering drug may be selected from biguanides (e.g., metformin, phenformin, and buformin), insulin (e.g., regular human insulin, NPH insulin, aspart insulin, lispro insulin, glargine insulin, detemir insulin, and levemir insulin), glucagon-like peptide 1 receptor agonists [GLP-1RA, such as albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, and extended-release glucagon], sodium-glucose cotransporter 2 inhibitors [SGLR2I, such as canagliflozin, empagliflozin, dapagliflozin, enalapril, valproate ... empagliflozin and ipragliflozin], dipeptidyl peptidase 4 inhibitors [DPP4I, such as bromocriptine, sitagliptin, vildagliptin, saxagliptin, linagliptin, anagliptin, teneligliptin, alogliptin, trelagliptin in), gemigliptin, dutogliptin, omarigliptin, berberine, and lupeol), α-glucosidase inhibitors [AGIs, such as miglitol, acarbose, and voglibose], thiazolidinediones [TZDs, such as pioglitazone, rosiglitazone, lobeglitazone, troglitazone, ciglitazone, darglitazone, englitazone, netoglitazone, ), rivoglitazone, and mifepristone], meglitinides (such as glinide, nateglinide, and mitiglinide), sulfonylureas (SU; such as amobutamide, acetophenonesulfonylcyclohexamide, chlorpropamide, tolbutamide, tolsulfuronamide, glipizide (Liganduzumab), gliclazide, glyburide, glyburide (such as Micronase), glibornamide, gliquidone, glisipad, glypyiramide, glimepiride, amarylamide, and glimiprime], amylin analogs (such as pramlintide), proprotein convertase subtilisin kexin-9 type inhibitors [PCSK9I;such as evolocumab, bococizumab, alirocumab, 1D05-IgG2, RG-7652, LY3015014, RNAi therapeutics ALN-PCS02, AMG-145, and REGN727 / SAR236553], glucokinase activators [GKAs such as MK-0941, RO-28-1675, and AZD1656], PPAR agonists / modulators, glucagon receptor antagonists, CC chemokine receptor type 2 (CCR2) antagonists, interleukin-1 modulators, G-protein coupled receptor agonists, gastrointestinal peptide agonists other than GLP-1, S GLT1 and SGLT1 / SGLT2 dual inhibitors (excluding SGLT2-only inhibitors), 11β-HSD1 inhibitors, diacylglycerol acyltransferase (DGAT)-1 inhibitors, cannabinoids, liver carnitine palmitoyltransferase 1 (CPT1) inhibitors, fibroblast growth factor (FGF)-21 agonists, glucocorticoid receptor antagonists, heat shock protein (HSP) inducers, melanocortin-4 receptor (MC4R) agonists, oral antidiabetic agents containing a tetrahydrotriazine ring, glimins, protein tyrosine phospholipase 1B (PTP1B) inhibitors, sirtuin 1 (SIRT1) activators, and microbiome modulators.

[0131] In certain embodiments, the other therapeutic agent is a lipid-lowering agent, which can be selected from statins (e.g., HMG-CoA reductase inhibitors, such as simvastatin, atorvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, ... tin), mevastatin, pantethine, elastase, and probucol], benzoic acids [e.g., bezafibrate (e.g., Bezalip), ciprofibrate (e.g., Modalim), clofibrate, gemfibrozil (e.g., Lopid), fenofibrate (e.g., TriCor), clindamycin (e.g., Lipoclin), lifibrate, clofibrate aluminum, bisfibrate, edoxaban, and gemfibrozil], nicotinic acids (e.g., niacin, inositol nicotinate, niacinamide, and acipimox), bile acid sequestrants (e.g., cholestyramine (e.g., ), colesevelam (such as ), colestipol (such as ), cholesterol meglumine, dholestyramine, and desmin), ezetimibe (such as Zetia), proprotein convertase subtilisin / kexin-9 type inhibitors [PCSK9I, such as evolocumab, bococizumab, alirocumab, 1D05-IgG2, RG-7652, LY3015014, RNAi therapeutic ALN-PCS02, AMG-145, and REGN727 / SAR236553], microsomal triglyceride transfer protein inhibitors (MTTPI, such as lomitapide and JTT-130), apolipoprotein B inhibitors (apoBI, such as mipomersen (such as Kynamro) ), diacylglycerol acyltransferase 1 (DGAT1) inhibitors (such as pradigastat), angiopoietin-like protein 3 inhibitors (such as REGN1500), cholesteryl ester transfer protein (CETP) inhibitors [such as anacetrapib and evacetrapib], peroxisome proliferator-activated receptor (PPAR) α / γ agonists, acyl-CoA inhibitors, incretin mimetic inhibitors, angiopoietin-like protein 3 (ANGPTL3) inhibitors, angiopoietin-like protein 4 (ANGPTL4) inhibitors, inhibitors targeting apoC-III, and selective peroxisome proliferator-activated receptor modulators (SPPARMs).

[0132] In some embodiments, the additional therapeutic agent is an anti-obesity drug, which can be selected from, for example, orlistat (e.g., Xenical), lorcaserin (e.g., Belviq), phentermine, topiramate, diethylpropion, phendimetrazine, benzphetamine, and a mixture of phendimetrazine and benzphetamine.

[0133] In some embodiments, the additional therapeutic agent is a bile acid analog, such as can be selected from obeticholic acid, ursodeoxycholic acid, and cholylsarcosine.

[0134] In some embodiments, the additional therapeutic agent may be selected from the group consisting of farnesoid X receptor (FXR) agonists, FXR inhibitors, transmembrane G protein-coupled receptor 5 (TGR5) agonists, and TGR5 inhibitors.

[0135] In some embodiments, the additional therapeutic agent can be selected from insulin, metformin, sitagliptin, colesevelam, glipizide, simvastatin, atorvastatin, ezetimibe, fenofibrate, niacin, orlistat, lorcaserin, phentermine, topiramate, obeticholic acid, and ursodeoxycholic acid.

[0136] These combination therapies described herein may include co-administration (wherein the two or more therapeutic agents may be in the same formulation or in separate formulations), as well as separate administration, in which case the polypeptides described herein may be administered before, simultaneously with, or after the other therapeutic agents.

[0137] The polypeptides described herein (and any other therapeutic agents) can be administered in a suitable manner, including parenteral, intrapulmonary and intranasal; local treatment or intralesional administration can also be performed. In some embodiments, the polypeptides described herein can be administered parenterally. Parenteral administration can include intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. In some embodiments, the polypeptides described herein can be administered subcutaneously. In some embodiments, the polypeptides described herein can be administered intravenously. Administration can be by any suitable means, such as by injection or infusion, such as intravenous or subcutaneous injection or infusion, which depends in part on whether the administration is short-term or long-term. Various dosage regimens are also considered, including single or multiple administrations, large doses, and pulse injections, such as at various time points.

[0138] The polypeptides described herein will be formulated, dosed, and administered in a manner consistent with conventional medical practice. Factors to be considered herein may include, for example, the specific condition to be treated, the specific mammal to be administered, the clinical condition of the individual patient, the cause of disease, the site of administration, the method of administration, the dosage regimen, and other factors well known to pharmacists. The polypeptides described herein need not, but may optionally, be formulated with one or more other agents currently used to prevent or treat the condition to be treated. The effective amount of these other agents will depend on the amount of the polypeptides described herein present in the formulation, the type of condition or treatment, and the other factors described above.

[0139] For the prevention or treatment of disease, the appropriate dosage of the polypeptides described herein (when used alone or in combination with one or more other therapeutic agents) may depend on the type of disease to be treated, the severity and course of the disease, whether the polypeptide is used for preventive or therapeutic purposes, previous treatment, the patient's clinical history and response to the polypeptide, and the judgment of the attending physician. The polypeptides described herein may be administered to the patient in a suitable one-time or series of doses. Depending on the type and severity of the disease, the polypeptides described herein may be administered to the patient, for example, in a single dose or in multiple doses, or by continuous infusion. For repeated administration over several days or longer, depending on the condition, treatment may continue until the desired symptoms of the disease are suppressed. The polypeptides described herein may be administered intermittently, for example, every day, every two days, every three days, every week, or every two or three weeks (e.g., so that the patient will receive more than one dose, such as about 2 to about 20 doses, such as about 6 doses of the polypeptide). The initial dose may be higher, followed by one or more lower doses of the agent.

[0140] In certain embodiments, a fixed dosage regimen can be used to administer the polypeptides described herein to a subject. However, other dosage regimens can be used depending on the factors discussed above. The progress of the disease or treatment can be easily monitored using conventional techniques and assays for the disease or condition being treated.

[0141] The examples are provided for illustrative purposes and should not be construed as limiting the scope of the present invention.

[0142] Example

[0143] This example uses a mouse nonalcoholic steatohepatitis (NSAH) model to evaluate the effects of hepalatide (L47) on NASH metabolic levels and pathological changes, to determine whether L47 has an ameliorative effect on NASH lesions, and to provide a reference for preclinical pharmacodynamic evaluation of L47.

[0144] 1. Experimental Materials and Methods

[0145] 1. Experimental Materials

[0146] Hepalatide (L47); Preparation method: Weigh the required L47 into a 15ml centrifuge tube, add the required volume of 1X PBS buffer, shake well, and use immediately after preparation.

[0147] Preparation method: Preparation of PBS buffer stock solution:

[0148] Solution A: 0.2M Na2HPO4: weigh 71.6g Na2HPO4-12H2O and 8g NaCl and dissolve in 1000ml water;

[0149] Solution B: 0.2M NaH2PO4: weigh 31.2g NaH2PO4-2H2O and 8g NaCl and dissolve in 1000ml water;

[0150] Prepare 20X PBS buffer: Mix 81 ml of Solution A with 19 ml of Solution B to make 100 ml.

[0151] Preparation of 1X PBS buffer: Take 50 ml of 20X PBS buffer and dilute to 1 L.

[0152] 2. Experimental Animals

[0153] Breed and strain: C57BL6 mice; Grade: SPF; Age: 6-8 weeks; Gender: male; Source: Nanjing University-Nanjing Institute of Biomedicine SCXK (Su) 2015-0001, Animal Quality Certificate Numbers: 201604593 and 201605069.

[0154] 3. Experimental conditions

[0155] License number: SCXK(Shanghai)2014-0004 from the Department of Laboratory Animal Science, Fudan University.

[0156] Drinking water: Filter-sterilize tap water in autoclaved drinking bottles for free drinking. Change water twice a week.

[0157] High sugar water formula: Glucose: 18.9g, fructose: 23.1g dissolved in 1L drinking water

[0158] Ordinary feed (basic feed, fat content accounts for 12%): complete nutritional mouse pellet feed, Co 60 Irradiation sterilization, from the Department of Laboratory Animal Science, Fudan University.

[0159] High-fat diet: purchased from Research Diet Company, USA, product number: D12492, fat content: 60%.

[0160] C57BL6 mice were housed in the IVC with ad libitum access to food and water, with 4-5 mice per cage. Bedding was changed every other day. Body weights were measured weekly, and feed consumption was recorded for each cage. Throughout the experiment, the experimental husbandry and experimental procedures of mice were approved by the Ethics Committee of the School of Basic Medical Sciences, Fudan University.

[0161] 4. Animal Grouping and Treatment

[0162] 4.1 Dosage setting and grouping

[0163] 4.1.1 Normal control group (Control): Ordinary block feed + ordinary water, a total of 14 mice, 6 mice were killed at 8 weeks, and 8 mice were killed at 16 weeks.

[0164] 4.1.2 Model group (HFC-F / G): high-fat diet + high-sugar water, a total of 9 mice, 3 of which were killed at 8 weeks and 6 at 16 weeks.

[0165] 4.1.3 Low-dose group 1 (HFC-F / G+HL1): high-fat diet + high-sugar water + L47 20 mg / kg (10 mg / kg*2 / d, i.e. once in the morning and once in the afternoon), a total of 10 mice, 3 mice were killed at 8 weeks, and 7 mice were killed at 16 weeks.

[0166] 4.1.4 High-dose group 1 (HFC-F / G + HH1): high-fat diet + high-sugar water + L4760 mg / kg (30 mg / kg*2 / d, i.e. once in the morning and once in the afternoon), a total of 10 mice, 3 of which were killed at 8 weeks and 7 at 16 weeks.

[0167] 4.1.5 Low-dose group 2 (HFC-F / G+HL2): high-fat diet + high-sugar water + L47 20 mg / kg (10 mg / kg*2 / d, i.e. once in the morning and once in the afternoon, drug intervention started 8 weeks after the start of the experiment), a total of 5 mice, and were killed after 16 weeks.

[0168] 4.1.6 High-dose group 2 (HFC-F / G+HH2): high-fat diet + high-sugar water + L4760mg / kg (30mg / kg*2 / d, i.e. once in the morning and once in the afternoon, drug intervention started 8 weeks after the start of the experiment), a total of 5 mice, were killed after 16 weeks.

[0169] The dosing concentration of L47 in the low-dose group was 5 mg / ml; the dosing concentration of L47 in the high-dose group was 10 mg / ml.

[0170] Route of administration: subcutaneous injection.

[0171] 5. Reagents and instruments required for testing

[0172] 5.1 Main Reagents

[0173] 5.1.1 Chloral hydrate, provided by Sinopharm Chemical Reagent Co., Ltd.

[0174] 5.1.2 NA2HPO4-12H2O, batch number: 20150603, Sinopharm Chemical Reagent Co., Ltd.

[0175] 5.1.3 NaH2PO4-2H2O, batch number: 20120330, Sinopharm Chemical Reagent Co., Ltd.

[0176] 5.1.4 Glucose, product number: G8270-5KG, Sigma;

[0177] 5.1.5 Fructose, product number: F3510-5KG, Sigma;

[0178] 5.1.6 10% formalin, product number: HT501128-4L, Sigma;

[0179] 5.1.7 OTC, product number: 4583, Sakura Company;

[0180] 5.1.8 75% ethanol, batch number: 20141216, Sinopharm Chemical Reagent Co., Ltd.

[0181] 5.1.9 Blood glucose test strips, batch number: 1616530210, Omron.

[0182] 5.2 Test Kit

[0183] 5.2.1 Serum biochemistry kit:

[0184] Total cholesterol (TC), triglycerides (TG), total bilirubin (TBIL), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), alkaline phosphatase (ALP), albumin (ALB), aspartate transaminase (AST), and alanine transaminase (ALT) were provided by Shanghai Aidikang Company. The assay was performed using an automatic biochemical analyzer.

[0185] Total bile acid (TBA) and very low-density lipoprotein (VLDL) were provided by Nanjing Jiancheng Bioengineering Institute.

[0186] 5.2.2 Liver biochemistry kit:

[0187] Hydroxyproline and free fatty acid (FFA) kits: catalog numbers A030-3 and A042-1, respectively, provided by Nanjing Jiancheng Bioengineering Institute;

[0188] Triglyceride (TG) and cholesterol (TC): Product numbers are E1013-105 and E1015, respectively, provided by Beijing Pulilai Gene Technology Co., Ltd.

[0189] 5.2.3 Insulin ELISA kit, catalog number: EZRMI-13K, Millipore

[0190] 5.3 Main instruments

[0191] 5.3.1 Electronic analytical balance, Sartorius;

[0192] 5.3.2 BAT-1B / 131126AA-18 liquid nitrogen tank, MVE Company;

[0193] 5.3.3 H2O-I-1-T ultrapure water purification device, Sartorius;

[0194] 5.3.4 Flex station 3 multi-function plate reader - calcium flux detection workstation;

[0195] 5.3.5 TS100 inverted microscope, Nikon Eclipse;

[0196] 5.3.6 VB-95 autoclave, Systec;

[0197] 5.3.7 HGM-112 blood glucose meter, Omron.

[0198] 6. Observation indicators

[0199] 6.1 General Observations

[0200] Each experimental group was given adequate feed and water daily and was allowed to eat freely. The sugar water group had its water changed twice a week. Except for the normal control group, the remaining feed in each group was weighed weekly and supplemented with 150 g, and the mice in each group were weighed weekly.

[0201] 6.2 Gross anatomical observation

[0202] At 8 and 16 weeks, the livers were dissected and separated after blood was taken under anesthesia, and the pathological changes of liver tissue and abdominal fat accumulation were observed grossly.

[0203] 6.3 Observation and measurement of body fat deposition

[0204] At 16 weeks, quantitative CT was used to locate and quantify subcutaneous, visceral, and brown fat in mice.

[0205] 6.4 Testing of blood glucose, glucose tolerance, and insulin resistance index

[0206] At 8 and 16 weeks, the mice were tested for fasting blood glucose and glucose tolerance (subcutaneous injection of glucose: 2.5 mg / g, prepared concentration: 250 mg / ml). Blood glucose levels were measured 0, 30, 60, 90, and 120 minutes after glucose injection, and the insulin resistance index was calculated based on the fasting insulin level.

[0207] 6.5 Blood biochemistry test

[0208] At 8 and 16 weeks, the mice were anesthetized and fasted (fasted for 12 h) and their blood was collected to measure serum TG, TC, ALB, ALP, ALT, AST, HDL-C, LDL-C, VLDL, TBIL, TBA, and insulin (Ins) levels.

[0209] 6.6 Liver biochemical tests

[0210] The livers were harvested at 8 and 16 weeks to measure the levels of TG, TC, free fatty acids (FFA), and hydroxyproline (HYP).

[0211] 6.7 Histological Observation

[0212] Liver tissue sections of mice at 8 and 16 weeks were stained with hematoxylin-eosin (HE), trichrome (Masson staining), Oil Red O (Oil Red O) staining, and apoptosis (TUNEL) staining.

[0213] 7. Data Processing

[0214] SPSS software was used for statistical analysis. All data were expressed as mean ± standard error (SEM). ANOVA analysis of variance was used to evaluate the experimental results of the measurement data. The LSD test was used for pairwise comparisons. The numerical values ​​of the statistical results were rounded to two decimal places.

[0215] 2. Experimental Results

[0216] 1. Effect of L47 on liver weight in C57BL6 mice

[0217] Depend on Figure 1 It can be seen that there was no significant difference in liver weight among the groups at 8 weeks, and there was an increasing trend in the model group.

[0218] Depend on Figure 2 It can be seen that at 16 weeks, the liver weight of mice in the model group was significantly higher than that in the normal control group (p < 0.001), and the liver weight of mice in the low-dose group 2 (HL2) was significantly lower than that in the model group (p < 0.05).

[0219] 2. Fat distribution and quantification in each group at 16 weeks

[0220] After micro CT scanning, the data analysis results were obtained from Figure 3 As shown in the figure, at 16 weeks, the subcutaneous fat, visceral fat, and brown fat of the model group mice were significantly higher than those of the normal control group. Subcutaneous fat decreased in high-dose group 1 (HH1), low-dose group 2 (HL2), and high-dose group 2 (HH2) compared with the model group. Except for the normal control group, there were no significant differences in visceral fat and brown fat in the other groups.

[0221] Liver histological changes at 3, 8, and 16 weeks

[0222] 3.1 HE staining at 8 and 16 weeks

[0223] Depend on Figure 4 It can be seen that at 8 weeks, compared with the livers of mice in the normal control group, the liver cells in the model group formed fat vacuoles of varying sizes, accompanied by an increase in inflammatory cells; while the low- and high-dose groups only formed a few and smaller fat vacuoles, and there were also fewer inflammatory cells.

[0224] Depend on Figure 5 It can be seen that at 16 weeks, compared with the livers of mice in the normal control group, the model group and high-dose group 1 (HH1) developed severe fatty degeneration and obvious inflammatory cell infiltration, while the fatty degeneration and inflammatory response in the other groups were relatively mild.

[0225] 3.2 Oil Red O staining at 8 and 16 weeks

[0226] Depend on Figure 6 It can be seen that at 8 weeks, compared with the livers of mice in the normal control group, larger lipid droplet vacuoles were formed in the model group, while smaller and fewer vacuoles were formed in the treatment group.

[0227] Depend on Figure 7It can be seen that at 16 weeks, compared with the livers of mice in the normal control group, the model group had large fat vacuoles formed in the hepatocytes, which were larger and more numerous than at 8 weeks. Compared with the model group, fat accumulation in low-dose group 1 (HL1) and high-dose group 1 (HH1) was only slightly reduced, but fat accumulation in low-dose group 2 (HL2) and high-dose group 2 (HH2) was significantly reduced, with fewer and smaller fat vacuoles formed.

[0228] 3.3 Masson staining at 8 and 16 weeks

[0229] Depend on Figure 8 It can be seen that at 8 weeks, the model group formed more fibrous cords compared with the normal control group, while the other groups had no significant differences compared with the model group.

[0230] Depend on Figure 9 It can be seen that at 16 weeks, compared with the livers of mice in the normal control group, the model group formed more and more obvious fibrous cords. There was no significant difference between the high-dose group 1 (HH1) and the low-dose group 1 (HL1) and the model group. The fibrous deposition in the high-dose group 2 (HH2) and the low-dose group 2 (HL2) decreased compared with the model group.

[0231] 3.4 TUNEL staining and quantification at 8 and 16 weeks

[0232] 3.4.1 TUNEL staining histology

[0233] Depend on Figure 10 It can be seen that compared with the normal control group at 8 weeks, a large number of typical apoptosis-positive cells were formed in the liver of the model group mice, and the cell apoptosis in the treatment group was effectively improved.

[0234] Depend on Figure 11 It can be seen that at 16 weeks, compared with the normal control group, a large number of typical apoptosis-positive cells were formed in the liver of the model group mice, and the apoptosis of cells in the low-dose group 2 (HL2) and high-dose group 2 (HH2) was effectively improved. However, the apoptosis of cells in the low-dose group 1 (HL1) and high-dose group 1 (HH1) did not improve.

[0235] 3.4.2 TUNEL semi-quantitative counting

[0236] Depend on Figure 12 As shown in Figure 3, the number of typical TUNEL-positive cells in the liver of the model group was significantly increased compared with the normal control group at 8 weeks (p < 0.001, p < 0.01). The number of apoptotic bodies in the treatment group was significantly decreased compared with the model group (p < 0.001, p < 0.001).

[0237] Depend on Figure 13It can be seen that at 16 weeks, compared with the normal control group, the number of typical TUNEL-positive cells in the liver of mice in the model group was significantly increased (p≤0.01), and the number of apoptotic bodies in the low-dose group 2 (HL2) and high-dose group 2 (HH2) was significantly decreased (p≤0.01, p≤0.01).

[0238] Glucose tolerance, insulin levels and resistance index of mice at 4, 8 and 16 weeks

[0239] 4.1 Fasting blood glucose levels and glucose tolerance test of mice at 8 and 16 weeks

[0240] Depend on Figure 14 It can be seen that compared with the normal control group, the blood glucose level in the model group continued to rise for 60 minutes and then did not decrease significantly, but there were significant differences at 90 minutes (p < 0.001) and 120 minutes (p ≤ 0.001). Compared with the normal control group, the blood glucose level in the treatment group decreased significantly at 90 minutes (p < 0.05, p < 0.01) and 120 minutes (p < 0.01); compared with the normal control group, the blood glucose level in the model group continued to rise for 60 minutes and then did not decrease significantly, but there were significant differences at 90 minutes (p < 0.001) and 120 minutes (< 0.01). Compared with the treatment group, the blood glucose level in the treatment group decreased significantly at 90 minutes (p < 0.05, p ≤ 0.001) and 120 minutes (p < 0.05).

[0241] Depend on Figure 15 As shown, at 16 weeks, compared with the normal control group, blood glucose levels in the model group continued to rise until 60 minutes, after which they did not decline significantly, with significant differences observed at 90 minutes (p ≤ 0.001) and 120 minutes (p < 0.001). Blood glucose levels in the treatment group showed a downward trend compared with the model group at 90 minutes and 120 minutes. Compared with the normal control group, blood glucose levels in the model control group were significantly elevated, with significant differences observed at 90 minutes (p < 0.01) and 120 minutes (p ≤ 0.01). However, compared with the treatment group, blood glucose levels rapidly declined after 60 minutes, with no significant difference observed.

[0242] 4.2 Insulin levels and resistance index in mice at 16 weeks

[0243] 4.2.1 Fasting insulin levels in mice at 16 weeks

[0244] Depend on Figure 16 It can be seen that compared with the normal control group, the insulin level in the model group was significantly increased (p < 0.001), and the insulin level in low-dose group 1 (HL1), high-dose group 1 (HH1) and high-dose group 2 (HH2) was significantly decreased compared with it (p < 0.001, p ≤ 0.001, p < 0.001), and the insulin level in low-dose group 2 (HL2) showed a downward trend compared with the model group.

[0245] 4.2.2 Insulin resistance index (HOMA-RI) of mice at 16 weeks

[0246] Depend on Figure 17 It can be seen that compared with the normal control group, the HOMA-RI level of insulin resistance in the model group was significantly increased at 16 weeks (p≤0.001), and the low-dose group 1 (HL1) and high-dose group 1 (HH1) were significantly decreased compared with them (p<0.05, p<0.05), the high-dose group 2 (HH2) showed a downward trend, while there was no significant difference in the low-dose group 2 (HL2).

[0247] Serum biochemical tests at 5, 8, and 16 weeks

[0248] 5.1 Effect of L47 on serum ALB and ALP in C57BL6 mice at 16 weeks

[0249] Depend on Figure 18 As can be seen, at 16 weeks, the ALB level in the model group increased compared with the normal control group (p < 0.05), while that in the low-dose group 2 (HL2) and the high-dose group 2 (HH2) decreased (p < 0.001, p < 0.001), while there were no differences in the other groups. There was no significant difference in ALP levels among the groups.

[0250] 5.2 Effects of L47 on serum HDL-C and LDL-C in C57BL6 mice at 8 and 16 weeks

[0251] Depend on Figure 19 It can be seen that at 8 weeks, the levels of HDL-C and LDL-C in the model group were increased compared with the normal control group, the levels of HDL-C and LDL-C in the low-dose group 1 (HL1) were decreased compared with the model group, and only LDL-C was decreased in the high-dose group 1 (HH1).

[0252] Depend on Figure 20 It can be seen that at 16 weeks, the levels of HDL-C and LDL-C in the model group were significantly increased compared with the normal control group (p < 0.001, p ≤ 0.001). Except for the high-dose group 2 (HH2), the HDL-C levels in the treatment groups were decreased compared with the model group (p < 0.01). Only the low-dose group 1 (HL1) and the high-dose group 1 (HH1) showed a decrease in LDL-C level (p ≤ 0.001, p < 0.01).

[0253] 5.3 Effect of L47 on serum VLDL in C57BL6 mice at 16 weeks

[0254] Depend on Figure 21 It can be seen that at 16 weeks, the VLDL level in the model group showed a downward trend compared with the normal control group. Except for the low-dose group 2 (HL2), the levels in the other groups were higher than those in the model group.

[0255] 5.4 Effects of L47 on serum ALT and AST in C57BL6 mice at 8 and 16 weeks

[0256] Depend on Figure 22 It can be seen that at 8 weeks, the ALT and AST levels in the model group increased compared with the normal control group, with the ALT increase being more significant (p < 0.001). The ALT level in the treatment group decreased significantly compared with the model group (p ≤ 0.001). The AST level showed a downward trend.

[0257] Depend on Figure 23 It can be seen that at 16 weeks, the ALT and AST levels in the model group were significantly increased compared with the normal control group (p < 0.01), the ALT and AST levels in the low-dose group 2 (HL2) were significantly decreased compared with the model group (p < 0.05), the ALT and AST levels in the high-dose group 2 (HH2) showed a downward trend, while the ALT and AST levels in the low-dose group 1 (HL1) and high-dose group 1 (HH2) did not decrease.

[0258] 5.5 Effects of L47 on serum TG and TC in C57BL6 mice at 8 and 16 weeks

[0259] Depend on Figure 24 It can be seen that at 8 weeks, the TG and TC levels in the model group increased compared with the normal control group, and the increase of TC was more obvious (p < 0.01). The TG and TC levels in the treatment group decreased significantly compared with the model group, among which the TC in the low-dose group 1 (HL1) decreased significantly (p < 0.05).

[0260] Depend on Figure 25 It can be seen that at 16 weeks, the TG and TC levels in the model group were significantly increased compared with the normal control group (p≤0.001, p<0.001), the TC level in the treatment group was significantly decreased compared with the model group (p<0.001, p<0.001, p≤0.001, p<0.05), and the TG level did not decrease.

[0261] Liver biochemical tests at 6, 8 and 16 weeks

[0262] 6.1 Effects of L47 on liver TG in C57BL6 mice at 8 and 16 weeks

[0263] Depend on Figure 26 It can be seen that at 8 weeks, the TG level in the model group was significantly increased compared with the normal control group (p < 0.001), and the TG level in the treatment group was significantly decreased compared with that in the control group (p ≤ 0.001, p < 0.001).

[0264] Depend on Figure 27It can be seen that at 16 weeks, the TG level of the model group was significantly increased compared with the normal control group (p≤0.001), and the TG level of low-dose group 2 (HL2) and high-dose group 2 (HH2) was significantly decreased compared with the normal control group (p<0.01, p<0.05), and the TG level of low-dose group 1 (HL1) and high-dose group 1 (HH1) showed a downward trend. 6. Effect of L47 on TC in the liver of C57BL6 mice at 28 weeks and 16 weeks

[0265] Depend on Figure 28 It can be seen that at 8 weeks, the liver TC level in the model group was significantly increased compared with the normal control group (p < 0.01), while that in the treatment group was significantly decreased (p < 0.001, p ≤ 0.001). Figure 29 It can be seen that at 16 weeks, the TC level in the model group was significantly increased compared with the normal control group (p < 0.001), and the level in the treatment group was significantly decreased compared with the normal control group (p < 0.001, p < 0.001, p < 0.001, p < 0.001). 6. Effect of L47 on hydroxyproline in the liver of C57BL6 mice at 38 weeks and 16 weeks

[0266] Depend on Figure 30 It can be seen that at 8 weeks, the liver hydroxyproline level in the model group was significantly increased compared with the normal control group (p < 0.001), and there was a downward trend in the treatment group. Figure 31 It can be seen that at 16 weeks, the liver hydroxyproline level in the model group was significantly increased compared with the normal control group (p < 0.01), and the level in low-dose group 2 (HL2) and high-dose group 2 (HH2) was decreased compared with it, and HH2 was more significant (p < 0.05), and the levels in low-dose group 1 (HL1) and high-dose group 1 (HH1) were higher.

[0267] 6.4 Effects of L47 on FFA in the Liver of C57BL6 Mice at 8 and 16 Weeks

[0268] Depend on Figure 32 It can be seen that at 8 weeks, the liver FFA level in the model group was significantly increased compared with the normal control group (p≤0.001), and there was a downward trend in the treatment group (the high-dose group was statistically significant (p<0.05)).

[0269] Depend on Figure 33 It can be seen that at 16 weeks, the liver hydroxyproline level in the model group was significantly increased compared with the normal control group, while the level in the treatment group was decreased compared with it.

[0270] 3. Experimental Conclusion

[0271] (I) Effect of L47 on fat deposition in C57BL6 mice

[0272] 1. Effect of L47 on body fat deposition in C57BL6 mice

[0273] Weekly weight recording of mice revealed a significant decrease in weight in the L47-treated group compared with both the model and control groups at 8 weeks. Gross observation of abdominal fat deposition in the mice revealed a significant effect in the treatment group. At 16 weeks, body weight differences between the treatment and model groups were similar, with the exception of a 2% decrease in the low-dose group. There was no significant difference in abdominal fat deposition between the groups. In vivo CT scans of quantified body fat revealed a significant decrease in subcutaneous fat in the L47-treated group compared with the model group at 16 weeks. Furthermore, L47 had no significant effect on visceral or subcutaneous fat.

[0274] 2. Effect of L47 on liver fat deposition in C57BL6 mice

[0275] Gross observation of liver changes in this study revealed that at 8 weeks, the livers in the treatment group showed improvement compared to the model group, with normal color and lighter liver weight. Liver triglyceride and free fatty acid levels decreased significantly. Liver HE staining and Oil Red O staining also showed that the treatment group had fewer lipid droplets than the model group. At 16 weeks, the treatment effect was more pronounced in low-dose Group 2 and high-dose Group 2 than in the model group, with liver color approaching normal and liver weight being lighter, particularly in low-dose Group 2. Liver triglyceride levels decreased significantly in low-dose Group 2 and high-dose Group 2. Liver free fatty acid levels showed a downward trend in the treatment group compared to the model group. Liver HE staining and Oil Red O staining also showed that the low-dose Group 2 and high-dose Group 2 formed fewer and smaller lipid droplets than the model group.

[0276] 3. Effect of L47 on serum fat deposition in C57BL6 mice

[0277] This experiment detected the serum triglyceride level and found that the level in the treatment group was lower than that in the model group at 8 weeks, and there was no significant difference between the treatment group and the model group at 16 weeks.

[0278] In summary, observations of lipid deposition in mice at 8 and 16 weeks of age revealed that L47 effectively reduced subcutaneous fat, liver fat, and serum fat deposition in C57BL6 mice in the short term in a dose-dependent manner, but the improvement decreased with prolonged intervention. L47 had no significant effect on visceral fat or subcutaneous fat.

[0279] (II) Effects of L47 on metabolic levels in C57BL6 mice

[0280] This study detected serum metabolic indicators and found that at 8 weeks, the ALB level and LDL level of the treatment group decreased compared with the model group, while there were no significant differences in ALP, HDL, and VLDL levels. At 16 weeks, both HDL and LDL levels of the treatment group decreased compared with the model group, while there were no significant differences in ALP and VLDL levels. ALB decreased in low-dose group 2 and high-dose group 2 compared with the model group, while there were no significant differences in other indicators.

[0281] In addition, fasting serum insulin levels were detected by ELASA, glucose was injected intraperitoneally into mice for glucose tolerance test, and the insulin resistance index was further calculated based on the fasting blood glucose level. It was found that at 16 weeks, except for the low-dose group 2, the insulin levels and insulin resistance index of the treatment groups were significantly lower than those of the model group, and the blood glucose of the treatment groups was lower than that of the model group.

[0282] In summary, metabolic markers in mice at 8 and 16 weeks of age were assessed, and L47 was found to reduce ALB, HDL, and LDL levels, while having no effect on VLDL and ALP levels. L47 effectively lowered blood glucose and insulin levels and improved insulin resistance, with the effects becoming more pronounced with increasing dose and duration of treatment.

[0283] (III) Effects of L47 on liver function in C57BL6 mice

[0284] This study detected serum ALT and AST levels and found that ALT and AST levels in the treatment group decreased compared with the model group at week 8. At week 16, ALT and AST levels in low-dose group 2 and high-dose group 2 were significantly lower than those in the model group, while ALT and AST levels in high-dose group 1 showed an upward trend.

[0285] In addition, TUNEL staining of liver tissue sections revealed that at 8 weeks, apoptosis in the treatment group was significantly improved compared to the model group, with a significant decrease in the number of typical apoptosis-positive cells. At 16 weeks, apoptosis in both low-dose group 2 and high-dose group 2 was significantly improved compared to the model group, with a significant decrease in the number of typical apoptosis-positive cells.

[0286] In summary, through the observation of liver function indicators of mice at 8 and 16 weeks, it was found that L47 can effectively reduce the decline of ALT and AST levels in C57BL6 mice in the short term and improve cell apoptosis in a dose-dependent manner.

[0287] (IV) Effect of L47 on liver fibrosis in C57BL6 mice

[0288] In this study, MASSON staining and liver tissue hydroxyproline level testing revealed that at 8 weeks, the treatment group had fewer fiber cords and lower hydroxyproline levels than the model group. At 16 weeks, the low-dose group 2 and the high-dose group 2 had fewer fiber cords and significantly lower hydroxyproline levels than the model group.

[0289] In summary, through the observation of liver fibrosis indicators in mice at 8 and 16 weeks, it was found that L47 can effectively reduce the degree of liver fibrosis in C57BL6 mice in the short term, showing a dose-dependent manner.

[0290] Conclusion: Short-term (8 weeks) simultaneous or delayed administration of hepatocelide (L47) can improve hepatic fat accumulation, hepatocellular damage, insulin resistance, and liver fibrosis to varying degrees. With extended treatment (16 weeks), the improvement in insulin resistance persists. Sequence Listing <110> Shanghai Hepu Pharmaceutical Co., Ltd. <120> Drugs for the treatment of nonalcoholic fatty liver disease <130> 178034 <160> 48 <170> SIPOSequenceListing 1.0 <210> 1 <211> 60 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(60) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (60)..(60) <223> C-terminal NH2 <400> 1 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly Ala 35 40 45 Gly Ala Phe Gly Pro Gly Phe Thr Pro Pro His Gly 50 55 60 <210> 2 <211> 55 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(55) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (55)..(55) <223> C-terminal NH2 <400> 2 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly Ala 35 40 45 Gly Ala Phe Gly Pro Gly Phe 50 55 <210> 3 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 3 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly 35 40 45 <210> 4 <211> 40 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(40) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (40)..(40) <223> C-terminal NH2 <400> 4 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp 35 40 <210> 5 <211> 35 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(35) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (35)..(35) <223> C-terminal NH2 <400> 5 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro 35 <210> 6 <211> 30 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(30) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> ACETYLATION <222> (30)..(30) <223> C-terminal NH2 <400> 6 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp 20 25 30 <210> 7 <211> 25 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(25) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (25)..(25) <223> C-terminal NH2 <400> 7 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn 20 25 <210> 8 <211> 20 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(20) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (20)..(20) <223> C-terminal NH2 <400> 8 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro 20 <210> 9 <211> 58 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(58) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (58)..(58) <223> C-terminal NH2 <400> 9 Gly Gly Trp Ser Ser Lys Pro Arg Gln Gly Met Gly Thr Asn Leu Ser 1 5 10 15 Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His Gln Leu Asp Pro Ala 20 25 30 Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp Phe Asn Pro Asn Lys 35 40 45 Asp His Trp Pro Glu Ala Asn Gln Val Gly 50 55 <210> 10 <211> 57 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(57) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (57)..(57) <223> C-terminal NH2 <400> 10 Gly Leu Ser Trp Thr Val Pro Leu Glu Trp Gly Thr Asn Leu Ser Val 1 5 10 15 Pro Asn Pro Leu Gly Phe Phe Pro Asp His Gln Leu Asp Pro Ala Phe 20 25 30 Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp Phe Asn Pro Asn Lys Asp 35 40 45 His Trp Pro Glu Ala Asn Gln Val Gly 50 55 <210> 11 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> PALMITATE <222> (1)..(1) <223> N-terminal Plasma <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 11 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly 35 40 45 <210> 12 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> ACETYLATION <222> (1)..(1) <223> N-terminal Stearoyl <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 12 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly 35 40 45 <210> 13 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> ACETYLATION <222> (1)..(1) <223> N-terminal Chol <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 13 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly 35 40 45 <210> 14 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 14 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Val Lys Asp Asp Trp Pro Ala Ala Asn Gln Val Gly 35 40 45 <210> 15 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 15 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Lys Ala Asn Ser Glu Asn Pro Asp Trp Asp 20 25 30 Leu Asn Pro Asn Lys Asp Asn Trp Pro Asp Ala Asn Lys Val Gly 35 40 45 <210> 16 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <400> 16 Gly Gln Asn Leu Ser Thr Ser Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Arg Ala Asn Thr Ala Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp Thr Trp Pro Asp Ala Asn Lys Val Gly 35 40 45 <210> 17 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 17 Gly Lys Asn Ile Ser Thr Thr Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Arg Ala Asn Thr Arg Asn Pro Asp Trp Asp 20 25 30 His Asn Pro Asn Lys Asp His Trp Thr Glu Ala Asn Lys Val Gly 35 40 45 <210> 18 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 18 Gly Gln Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Leu Phe Arg Ala Asn Ser Ser Ser Pro Asp Trp Asp 20 25 30 Phe Asn Thr Asn Lys Asp Ser Trp Pro Met Ala Asn Lys Val Gly 35 40 45 <210> 19 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 19 Gly Lys Asn Leu Ser Ala Ser Asn Pro Leu Gly Phe Leu Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Arg Ala Asn Thr Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Lys Lys Asp Pro Trp Pro Glu Ala Asn Lys Val Gly 35 40 45 <210> 20 <211> 47 <212> PRT <213> Artificial Sequence <220> <221> PEPTIDE <222> (1)..(47) <223> Description of artificial sequences: synthetic peptides <220> <221> MYRISTATE <222> (1)..(1) <223> N-terminal Myr <220> <221> AMIDATION <222> (47)..(47) <223> C-terminal NH2 <400> 20 Gly Gln Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Leu Phe Arg Ala Asn Ser Ser Ser Pro Asp Trp Asp 20 25 30 Phe Asn Thr Asn Lys Asp Asn Trp Pro Met Ala Asn Lys Val Gly 35 40 45 <210> twenty one <211> 60 <212> PRT <213> Hepatitis B virus <400> twenty one Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly Ala 35 40 45 Gly Ala Phe Gly Pro Gly Phe Thr Pro Pro His Gly 50 55 60 <210> 22 <211> 55 <212> PRT <213> Hepatitis B virus <400> 22 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly Ala 35 40 45 Gly Ala Phe Gly Pro Gly Phe 50 55 <210> 23 <211> 47 <212> PRT <213> Hepatitis B virus <400> 23 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly 35 40 45 <210> twenty four <211> 40 <212> PRT <213> Hepatitis B virus <400> twenty four Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp 35 40 <210> 25 <211> 35 <212> PRT <213> Hepatitis B virus <400> 25 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro 35 <210> 26 <211> 30 <212> PRT <213> Hepatitis B virus <400> 26 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp 20 25 30 <210> 27 <211> 25 <212> PRT <213> Hepatitis B virus <400> 27 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn 20 25 <210> 28 <211> 20 <212> PRT <213> Hepatitis B virus <400> 28 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro 20 <210> 29 <211> 58 <212> PRT <213> Hepatitis B virus <400> 29 Gly Gly Trp Ser Ser Lys Pro Arg Gln Gly Met Gly Thr Asn Leu Ser 1 5 10 15 Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His Gln Leu Asp Pro Ala 20 25 30 Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp Phe Asn Pro Asn Lys 35 40 45 Asp His Trp Pro Glu Ala Asn Gln Val Gly 50 55 <210> 30 <211> 57 <212> PRT <213> Hepatitis B virus <400> 30 Gly Leu Ser Trp Thr Val Pro Leu Glu Trp Gly Thr Asn Leu Ser Val 1 5 10 15 Pro Asn Pro Leu Gly Phe Phe Pro Asp His Gln Leu Asp Pro Ala Phe 20 25 30 Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp Phe Asn Pro Asn Lys Asp 35 40 45 His Trp Pro Glu Ala Asn Gln Val Gly 50 55 <210> 31 <211> 47 <212> PRT <213> Hepatitis B virus <400> 31 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly 35 40 45 <210> 32 <211> 47 <212> PRT <213> Hepatitis B virus <400> 32 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly 35 40 45 <210> 33 <211> 47 <212> PRT <213> Hepatitis B virus <400> 33 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp His Trp Pro Glu Ala Asn Gln Val Gly 35 40 45 <210> 34 <211> 47 <212> PRT <213> Hepatitis B virus <400> 34 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Gly Ala Asn Ser Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Val Lys Asp Asp Trp Pro Ala Ala Asn Gln Val Gly 35 40 45 <210> 35 <211> 47 <212> PRT <213> Hepatitis B virus <400> 35 Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Lys Ala Asn Ser Glu Asn Pro Asp Trp Asp 20 25 30 Leu Asn Pro Asn Lys Asp Asn Trp Pro Asp Ala Asn Lys Val Gly 35 40 45 <210> 36 <211> 47 <212> PRT <213> Hepatitis B virus <400> 36 Gly Gln Asn Leu Ser Thr Ser Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Arg Ala Asn Thr Ala Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Asn Lys Asp Thr Trp Pro Asp Ala Asn Lys Val Gly 35 40 45 <210> 37 <211> 47 <212> PRT <213> Hepatitis B virus <400> 37 Gly Lys Asn Ile Ser Thr Thr Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Arg Ala Asn Thr Arg Asn Pro Asp Trp Asp 20 25 30 His Asn Pro Asn Lys Asp His Trp Thr Glu Ala Asn Lys Val Gly 35 40 45 <210> 38 <211> 47 <212> PRT <213> Hepatitis B virus <400> 38 Gly Gln Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Leu Phe Arg Ala Asn Ser Ser Ser Pro Asp Trp Asp 20 25 30 Phe Asn Thr Asn Lys Asp Ser Trp Pro Met Ala Asn Lys Val Gly 35 40 45 <210> 39 <211> 47 <212> PRT <213> Hepatitis B virus <400> 39 Gly Lys Asn Leu Ser Ala Ser Asn Pro Leu Gly Phe Leu Pro Asp His 1 5 10 15 Gln Leu Asp Pro Ala Phe Arg Ala Asn Thr Asn Asn Pro Asp Trp Asp 20 25 30 Phe Asn Pro Lys Lys Asp Pro Trp Pro Glu Ala Asn Lys Val Gly 35 40 45 <210> 40 <211> 47 <212> PRT <213> Hepatitis B virus <400> 40 Gly Gln Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp His 1 5 10 15 Gln Leu Asp Pro Leu Phe Arg Ala Asn Ser Ser Ser Pro Asp Trp Asp 20 25 30 Phe Asn Thr Asn Lys Asp Asn Trp Pro Met Ala Asn Lys Val Gly 35 40 45 <210> 41 <211> 3221 <212> DNA <213> Hepatitis B virus <400> 41 ttccactgcc ttccaccaag ctctgcagga tcccaaagtc aggggtctgt attttcctgc 60 tggtggctcc agttcaggaa cagtcaaccc tgctccaaat attgcctctc acatctcgtc 120 aatctccgcg aggactgggg accctgtgcc gaacatggag aacatcacat caggattcct 180 aggacccctg ctcgtgttac aggcggggtt tttcttgttg acaagaatcc tcacaatacc 240 gcagagtcta gactcgtggt ggacttctct caattttcta gggggatcac ccgtgtgtct 300 tggccaaaat tcgcagtccc caacctccaa tcactcacca acctcctgtc ctccaatttg 360 tcctggttat cgctggatgt gtctgcggcg ttttatcata ttcctcttca tcctgctgct 420 atgcctcatc ttcttattgg ttcttctgga ttatcaaggt atgttgcccg tttgtcctct 480 aattccagga tcaacaacaa ccagtacggg accatgcaaa acctgcacga ctcctgctca 540 aggcaactct atgtttccct catgttgctg tacaaaacct atggatggaa attgcacctg 600 tattcccatc ccatcgtcct gggctttcgc aaaataccta tgggagtggg cctcagtccg 660 tttctcttgg ctcagtttac tagtgccatt tgttcagtgg ttcgtagggc tttcccccac 720 tgtttggctt tcagctatat ggatgatgtg gtattggggg ccaagtctgt acagcatcgt 780 gagtcccttt ataccgctgt taccaattttt cttttgtctc tgggtataca tttaaaccct 840 aacaaaacaa aaagatgggg ttattcccta aacttcatgg tctacataat tggaagttgg 900 ggaacgttgc cacaggatca tattgtacaa aagatcaaac actgttttag aaaacttcct 960 gttaacagac ctattgattg gaaagtatgt caaagaattg tgggtcttttt gggctttgct 1020 gctccattta ctcaatgtgg atatcctgcc ttaatgcctt tgtatgcatg tatacaagct 1080 aaacaggctt ttactttctc gccaacttac aaggcctttc taagtaaaca gtatatgaac 1140 cttaccccg ttgctcggca acggcctggt ctgtgccaag tgtttgctga cgcaaccccc 1200 actggctggg gcttggccat aggccatcag cgcatgcgtg gaacctttgt ggctcctctg 1260 ccgatccata ctgcggaact cctagccgct tgttttgctc gcagccggtc tggagcaaag 1320 ctcatcggaa ctgaaattc tgtcgtcctc tcgcggaaat atacatcgtt tccatggctg 1380 ctaggctgta ctgccaactg gatccttcgc gggacgtcct ttgtttacgt cccgtcggcg 1440 ctgaatcccg cggacgaccc ctcgcggggc cgcttgggag tctctcgtcc ccttctccgt 1500 ctgccgttcc agccgaccac ggggcgcacc tctctttacg cggtctcccc gtctgtgcct 1560 tctcatctgc cggtccgtgt gcacttcgct tcacctctgc acgttgcatg gagaccaccg 1620 tgaacgccca tcagatcctg cccaaggtct tacataagag gactcttgga ctctcagcaa 1680 tgtcaatgac cgaccttgag gcctacttca aagactgtgt gtttaaggac tgggaggagc 1740 ttggggagga gattaggtta aaggtgtttg tattaggagg ctgtaggcat aaattggtct 1800 gcgcaccagc accatgcaac tttttcacct ctgcctaatc atctcttgta catgtcccac 1860 ttttcaagcc tccaagctgt gccttgggtg gctttggggc atggacattg acccttataa 1920 agaatttgga gctactgtgg agttactctc gtttttgcct tctgacttct ttccttccgt 1980 cagagatctc ctagacaccg cctcagctct gtatcgagaa gccttagagt ctcctgagca 2040 ttgctctcct caccatactg cactcaggca agccattctc tgctgggtgg aattgatgac 2100 tctagccacc tgggtgggta ataatttgga agatccagca tccagggatc tagtagtcaa 2160 ttatgttaat actaacatgg gtttaaagat caggcaacta ttgtggtttc atatatcttg 2220 tcttactttt ggaagacaga ctgtgctaga atatttggtc tctttcggag tgtggattcg 2280 cactcctcca gcttatagac caccaaatgc ccctatctta tcaacacttc cggagactac 2340 tgttgttaga cgacgggacc gaggcaggtc ccctagaaga agaactccct cgcctcgcag 2400 acgcagatct caatcgccgc gtcgcagaag atctcaatct cgggaatctc aatgttagta 2460 ttccttggac tcataaggtg ggaaatttta ctgggcttta ttcctctaca gtacctatct 2520 ttaatcctga atggcaaact ccttcctttc ctaagattca tttacaagag gacattatta 2580 ataggtgtca acaatttgtg ggccctctca ctgtaaatga aaagagaaga ctgaaattaa 2640 ttatgcctgc cagattctat cctacccaca ctaaatattt gcccttagac aaaggaatta 2700 aaccttatta tccagatcag gtagttaatc attacttcca aaccagacat tatttacata 2760 ctctttggaa ggctgggatt ctatataaga gggaaaccac acgtagcgca tcattttgcg 2820 ggtcaccata ttcttgggaa caagagctac atcatgggag gttggtcatc aaaacctcgc 2880 aaaggcatgg ggacgaacct ttctgttccc aaccctctgg gattctttcc cgatcatcag 2940 ttggaccctg cattcggagc caattcaaac aatccagatt gggacttcaa ccccatcaag 3000 gaccactggc cagcaggcaa ccaggtagga gtgggagcat tcgggccaag gctcacccct 3060 ccacacggcg gtattttggg gtggagccct caggctcagg gcatattggc cacagtgtca 3120 acaattcctc ctcctgcctc caccaatcgg cagtcaggaa ggcagcctac tcccatctct 3180 ccacctctaa gagacagtca tcctgaggcc atgcagtgga a 3221 <210> 42 <211> 3215 <212> DNA <213> Hepatitis B virus <400> 42 aactccacca ctttccacca aactcttcaa gatcccagag tcagggccct gtaccttcct 60 gctggtggct ccagttcaga aatagtgagc cctgctcaga atactgtctc tgccatatcg 120 tcaatcttat cgaagactgg ggaccctgta ccgaacatgg agaacatcgc atcaggactc 180 ctaggacccc tgctcgtgtt acaggcgggg tttttcttgt tgacaaaaat cctcacaata 240 ccacagagtc tagactcgtg gtggacttct ctcaattttc taggggaac acccgtgtgt 300 cttggccaaa attcgcagtc ccaaatctcc agtcactcac caacctgttg tcctccaatt 360 tgtcctgggt atcgctggat gtgtctgcgg cgttttatca tattcctctg catcctgctg 420 ctatgcctca tcttcttgtt ggttcttctg gactatcaag gtatgttgcc cgtttgtcct 480 ctaattccag gatcatcaac aaccagcacc ggaccatgca aaacctgcac aactcctgct 540 caaggaacct ctatgtttcc ctcatgttgc tgtacaaaac ctacggacgg aaactgcacc 600 tgtattccca tcccatcatc ttgggctttc gcaaattcc tatgggagtg ggcctcagtc 660 cgtttctctt ggctcagttt actagtgcca tttgttcagt ggttcgtagg gctttccccc 720 actgtctggc tttcagttat atcgatgatg tggttttgg ggccaagtct gtacaacatc 780 ttgagtccct ttataccgct gttaccaatt ttcttttgtc tttgggtata catttaaacc 840 ctcacaaaac aaaaagatgg ggatattccc ttaacttcat gggatatgta attgggagtt 900 ggggcacatt gccacaggaa catattgtac aaaaaatcaa aatgtgtttt aagaaacttc 960 ctgtaaacag gcctattgat tggaaagtat gtcaacgaat tgtgggtctt ttggggtttg 1020 ccgccccttt tacgcaatgt ggatatcctg ctttaatgcc tttatatgca tgtatacaag 1080 caaaacaggc ttttactttc tcgccaactt acaaggcctt tctaagtaaa cagtatatga 1140 acctttaccc cgttgctcgg caacggcctg gtctgtgcca agtgtttgct gacgcaaccc 1200 ccactggttg gggcttggcc attggccatc agcgcatgcg tgggaccttt gtgtctcctc 1260 tgccgatcca tactgcggaa ctcctagccg cttgttttgc tcgcagcagg tctggggcaa 1320 aactcatcgg gactgacaat tctgtcgtgc tctcccgcaa gtatacatca tttccatggc 1380 tgctaggctg tgctgccaac tggatcctgc gcgggacgtc ctttgtttac gtcccgtcgg 1440 cgctgaatcc cgcggacgac ccctcccggg gccgcttggg gctctaccgc ccgcttctcc 1500 gcctgttgta ccgaccgacc acggggcgca cctctcttta cgcggactcc ccgtctgtgc 1560 cttctcatct gccggaccgt gtgcacttcg cttcacctct gcacgtcgca tggagaccac 1620 cgtgaacgcc cacaggaacc tgcccaaggt cttgcataag aggactcttg gactttcagc 1680 aatgtcaacg accgaccttg aggcatactt caaagactgt gtgtttactg agtgggagga 1740 gttgggggag gagattaggt taaaggtctt tgtactagga ggctgttaggc ataaattggt 1800 gtgttcacca gcaccatgca actttttcac ctctgcctaa tcatctcatg ttcatgtcct 1860 actgttcaag cctccaagct gtgccttggg tggctttggg gcatggacat tgacccgtat 1920 aaagaatttg gagcttctgc ggagttactc tcttttttac cttctgactt ctttccttct 1980 attcgagatc ttctcgacac cgcctctgct ctgtatcggg aggccttaga gtctccggaa 2040 cattgttcac ctcaccatac ggcactcagg caagctattc tgtgttgggg tgagttgatg 2100 aatctagcca cctgggtggg aagtaatttg gaagatccag catccaggga attagtagtc 2160 ggctatgtca acgttaatat gggcctaaaa cttagacaac tattgtggtt tcacatttcc 2220 tgtcttactt ttgggagaga aactgttctt gaatatttgg tgtcttttgg agtgtggatt 2280 cgcactcctt ctgcatatag accaccaaat gcccctatcc tatcaacact tccggaaact 2340 actgttgtta gacgaagagg caggtcccct agaagaagaa ctccctcgcc tcgcagacga 2400 aggtctcaat cgccgcgtcg cagaagatct caatctcggg aatctcaatg ttagtattcc 2460 ttggacacat aaggtgggaa actttacggg gctttattct tctacggtac cttgttttaa 2520 tcctaaatgg caaactcctt cttttcctga cattcatttg caggaggaca ttgttgatag 2580 atgtaagcaa tttgtggggc cccttacagt aaatgaaaac aggagactaa aattattat 2640 gcctgctagg tttatccca atgttactaa atatttgccc ttagataaag ggatcaaacc 2700 gtattatcca gagtatgtag ttaatcatta cttccagacg cgacattatt tacacactct 2760 ttggaaagcg gggatcttat ataaaagaga gtccactcgt agcgcctcat tttgcgggtc 2820 accatattct tgggaacaag atctacagca tgggaggttg gtcttccaaa cctcgaaaag 2880 gcatggggac aaatctttct gtccccaatc ccctgggatt cttccccgat catcagttgg 2940 accctgcatt caaagccaac tcagaaaatc cagattggga cctcaacccg cacaaggaca 3000 actggccgga cgccaacaag gtgggagtgg gagcattcgg gccagggttc acccctcccc 3060 atggggggct gttggggtgg agccctcagg ctcagggcct actcacaact gtgccagcag 3120 ctcctcctcc tgcctccacc aatcggcagt caggaaggca gcctactccc ttatctccac 3180 ctctaaggga cactcatcct caggccatga agtgg 3215 <210> 43 <211> 3215 <212> DNA <213> Hepatitis B virus <400> 43 aattccacaa cattccacca agctctgcta gaccccagag tgaggggcct atactttcct 60[[ID=|17]] gctggtggct ccagttccgg aacagtaaac cctgttccga ctactgcctc acccatatcg 120 tcaatcttct cgaggactgg ggaccctgca ccgaacatgg agagcacaac atcaggattc 180 ctaggacccc tgctcgtgtt acaggcgggg tttttcttgt tgacaagaat cctcacaata 240 ccacagagtc tagactcgtg gtggacttct ctcaattttc tagggggagc acccacgtgt 300 cctggccaaa attcgcagtc cccaacctcc aatcactcac caacctcttg tcctccaatt 360 tgtcctggct atcgctggat gtgtctgcgg cgttttatca tattcctctt catcctgctg 420 ctatgcctca tcttcttgtt ggttcttctg gactaccaag gtatgttgcc cgtttgtcct 480 ctacttccag gaacatcaac taccagcacg ggaccatgca agacctgcac gagtcctgct 540 caaggaacct ctatgtttcc ctcttgttgc tgtacaaaac cttcggacgg aaactgcact 600 tgtattccca tcccatcatc ctgggctttc gcaagattcc tatgggagtg ggcctcagtc 660 cgtttctcct ggctcagttt actagtgcca tttgttcagt ggttcgtagg gctttcccc 720 actgtttggc tttcagttat atggatgatg tggtattggg ggccatgtct gtacaacatc 780 ttgagtccct ttttacctct attaccaatt ttcttttgtc tttgggtata catttgaacc 840 ctaataaac caaacgttgg ggctactccc ttaacttcat gggatatgta attggaagtt 900 ggggtacttt accgcaagaa catattgtac aaaaacttaa gcaatgtttt cgaaaactgc 960 ctgtaaatag acctattgat tggaagtat gtcagagaat tgtgggtctt ttgggctttg 1020 ctgccccttt tacacaatgt ggctatcctg ctttaatgcc tttatatgca tgtatacaat 1080 ctaagcaggc tttcactttc tcgccaactt acaaggcctt tctgtgtaaa caatatctga 1140 acctttaccc cgttgcccgg caacggtcag gtctctgcca agtgtttgct gacgcaaccc 1200 ccactggatg gggcttggct attggccatc gccgcatgcg tggaaccttt gtggctcctc 1260 tgccgatcca tactgcggaa ctcctagcag cttgttttgc tcgcagccgg tctggagcaa 1320 aacttatcgg caccgacaac tctgttgtcc tctctcggaa gtacacctcc tttccatggc 1380 tgctagggtg tgctgccaac tggatcctgc gcgggacgtc ctttgtttac gtcccgtcgg 1440 cgctgaatcc cgcggacgac ccgtctcggg gccgtttggg actctaccgt ccccttcttc 1500 atctgccgtt ccggccgacc acggggcgca cctctcttta cgcggtctcc ccgtctgtgc 1560 cttctcatct gccggaccgt gtgcacttcg cttcacctct gcacgtcgca tggagaccac 1620 cgtgaacgcc caccaggtct tgcccaaggt cttacataag aggactcttg gactctcagc 1680 aatgtcaacg accgaccttg aggcatactt caaagactgt ttgtttaagg actgggagga 1740 gttgggggag gagattaggt taaaggtctt tgtactagga ggctgtaggc ataaattggt 1800 ctgttcacca gcaccatgca actttttcac ctctgcctaa tcatctcatg ttcatgtcct 1860 actgttcaag cctccaagct gtgccttggg tggctttggg gcatggacat tgacccgtat 1920 aaagaatttg gagcttctgt ggagttactc tctttttgc cttctgactt cttccttct 1980 attcgagatc tcctcgacac cgcctctgct ctgtatcggg aggccttaga gtctccggaa 2040 cattgttcgc ctcaccatac agcactcagg caagctattc tttgttgggg tgagttgatg 2100 aatctggcca cctgggtggg aagtaatttg gaagacccag catccaggga attagtagcc 2160 agctatgtca atgttaatat gggcctaaaa atcagacaac tactgtggtt tcacatttcc 2220 tgtcttactt ttggaagaga aactgttctt gagtatttgg tatcttttgg agtgtggatt 2280 cgcactcctc ctgcttacag accaccaaat gcccctatct tatcaacact tccggaaact 2340 actgttgtta gacgacgagg caggtcccct agaagacgaa ctccctcgcc tcgcagacga 2400 aggtctcaat cgccgcgtcg cagaagatct caatctcggg aatctcaatg ttagtatccc 2460 ttggactcat aaggtgggaa actttactgg gctttattct tctactgtac ctgtctttaa 2520 tccagagtgg caaactccct cctttcctca cattcattta caggaggaca ttattaatag 2580 atgtcaacaa tatgtgggcc ctcttacagt taatgaaaaa agaagattaa aattattat 2640 gcctgctagg ttctatccta accttaccaa atatttgccc ttggacaaag gcattaacc 2760. attachment cttcaaaact aggcattatt tacatactct gtggaaggct ggcattctat aataagaga aactacacgc agcgcctcat tttgtgggtc accatattct tgggaacaag agctacagca tgggaggttg gtcttccaaa cctcgacaag gcatggggac aaatctttct gttcccaatc ctctggggatt ctttcccgat caccagttgg accctgcgtt cggagccaac tcaaacaatc cagattgggga cttcaacccc aacaaggatc actggccaga ggcaaatcag gtaggagcgg gagcattcgg gccagggttc accccaccac acggcggtct tttggggtgg agccctcagg ctcagggcat actgacaaca gtgccagtag 3120. 3180. cacctcctcc tgcctccacc aatcggcagt caggagaca gcctactccc atctctccac ctctaagaga cagtcatcct caggccatgc agtgg <210> 44 <211> 3182 <212> DNA <213> Description (Hepatitis B virus) <400> 44 60. aactccacaa ccttccacca aactctgcaa gatcccagag tgagaggcct gtatttccct gctggtggct ccagttcagg aacgttaac cctgttccga ctactgtctc tcccatatcg 120 tcaatcttct cgaggattgg ggaccctgcg ctgaacatgg agaacatcac atcaggattc 180 ctaggacccc tgctcgtgtt acaggcgggg tttttcttgt tgacaagaat cctcacaata 240 ccgcagagtc tagactcgtg gtggacttct ctcaattttc taggggaac taccgtgtgt 300 cttggccaaa attcgcagtc cccaacctcc aatcactcac caacctcctg tcctccaact 360 tgtcctggtt atcgctggat gtgtctgcgg cgttttatca tcttctctt catcctgctg 420 ctatgcctca tcttcttgtt ggttcttctg gactatcaag gtatgttgcc cgtttgtcct 480 ctaattccag gatcttcaac taccagcacg ggaccatgca gaacctgcac gactcctgct 540 caaggaacct ctatgtatcc ctcctgttgc tgtaccaaac cttcggacgg aaattgcacc 600 tgtattccca tcccatcatc ctgggctttc ggaaaattcc tatgggagtg ggcctcagcc 660 cgtttctcct ggctcagttt actagtgcca tttgttcagt ggttcgtcgg gctttcccc 720 actgtttggc tttcagttat atggatgatg tggtattggg ggccaagtct gtacagcatc 780 ttgagtccct ttttaccgct gttaccaatt ttcttttgtc tttgggtata catttaaacc 840 ctgacaaaac aaaaagatgg ggttactctt tacatttcat gggctatgtc attggaagtt 900 atgggtcatt gccacaagat cacatcatac aaaaaatcaa agaatgtttt cgaaaacttc 960 ctgttaacag acctattgat tggaaagtct gtcaacgtat tgtgggtctt ttgggttttg 1020 ctgccccttt tacacaatgt ggttatcctg ctttaaagcc tttgtatgca tgtattcaat 1080 ctaagcaggc tttcactttc tcgccaactt acaaggcctt tctgtgtaaa caatacctga 1140 acctttaccc cgttgcccgg caacggccag gtctgtgcca agtgtttgct gacgcaaccc 1200 ccactggctg gggcttggtc atgggccatc agcgcatgcg tggaaccttt ctggctcctc 1260 tgccgatcca tactgcggaa ctcctagccg cttgttttgc tcgcagcagg tctggagcaa 1320 acattctcgg gacggataac tctgttgttc tctcccgcaa atatacatcg tttccatggc 1380 tgctaggctg tgctgccaac tggatcctgc gcgggacgtc ctttgtttac gtcccgtcgg 1440 cgctgaatcc cgcggacgac ccttctcggg gtcgcttggg actctctcgt ccccttctcc 1500 gtctgccgtt tcgaccgacc acggggcgca cctctcttta cgcggactcc ccgtctgtgc 1560 cttctcatct gccggaccgt gtgcacttcg cttcacctct gcccgtcgca tggagaccac 1620 cgtgaacgcc caccgagtct tgcccaaggt cttacataag aggactcttg gactctctgt 1680 aatgtcaacg accgaccttg aggcatactt caaagactgt ttgttcaaag actgggagga 1740 gttgggggag gagattagat taaaggtctt tgtactagga ggctgtaggc ataaattggt 1800 ctgcgcacca gcaccatgca actttttcac ctctgcctaa tcatctcttg ttcatgtcct 1860 actgttcaag cctccaagct gtgccttggg tggctttagg gcatggacat cgatccttat 1920 aaagaatttg gagctactgt ggagttactc tcgtttttgc cttctgactt ctttccttca 1980 gtacgagatc ttctagatac cgcctcagct ctgtatcggg aagccttaga gtctcctgag 2040 cattgttcac ctcaccatac tgcactcagg caagcagttc tgtgctgggg ggaactaatg 2100 actctagcta cctgggtggg tggtaatttg gaagatccaa catccaggga cctagtagtc 2160 agttatgtca acactaatat gggcctaaag ttccggcaac tattgtggtt tcacatttct 2220 tgtctcactt ttggaagaga aacagtttta gagtatttgg tgtctttcgg agtgtggatt 2280 cgcactcctc cagcttatag accaccaaat gcccctatct tatcaacact tccggagact 2340 actgttgtta gacgacgagg caggtcccct agaagaagaa ctccctcgcc tcgcagacga 2400 aggtctcaat cgccgcgtcg cagaagatct caatctcggg aatctcaatg ttagtattcc 2460 ttggactcat aaggtgggaa actttacggg gctttattct tctactgtac ctgtctttaa 2520 ccctcattgg aaaacaccct cttttcctaa tatacattta caccaagaca tttcaaaaa 2580 atgtgaacaa tttgtaggcc cactcacagt caatgaaaaa agaagactgc aattgattat 2640 gcctgctagg tttatccaa atgttaccaa atatttgcca ttggataagg gtatcaaacc 2700 ttattaccca gaacatctag ttaatcatta cttccaaacc agacattatt tacacactct 2760 atggaaggcg ggtatattat ataagagaga aacaacacat agcgcctcat ttgtggggtc 2820 accatattct tgggaacaaa agctacagca tggggcagaa tctttccacc agcaatcctc 2880 tgggattct tcccgaccac cagttggatc cagccttcag agcaaacacc gcaaatccag 2940 attgggactt caatcccaac aaggacacct ggccagacgc caacaaggta ggagctggag 3000 cattcgggct gggattcacc ccaccgcacg gaggcctttt ggggtggagc cctcaggctc 3060 agggcatact acaaaccttg ccagcaaatc cgcctcctgc ctctacccat cgccagtcag 3120 gaaggcagcc taccccgctg tctccacctt tgagaaacac tcatcctcag gccatgcagt 3180 gg 3182 <210> 45 <211> 3212 <212> DNA <213> Hepatitis B virus <400> 45 ttccacagca ttccaccaag ctctgcagga tcccaaagta agaggcctgt attttcctgc 60 tggtggctcc agttccggaa cagtgagccc tgttccgact actgcctcac tcatctcgtc 120 aatcttctcg aggattgggg accctgcacc gaacatggaa ggcatcacat caggattcct 180 gggacccctg ctcgtgttac aggcggggtt tttcttgttg acaaaaatcc tcacaatacc 240 gcagagtcta gactcgtggt ggacttctct caattttcta gggggagctc ccgtgtgtct 300 tggccaaaat tcgcagtccc caacctccaa tcactcacca acctcttgtc ctccgatttg 360 tcctggctat cgctggatgt gtctgcggcg ttttatcatc ttcctcttca tcctgctgct 420 atgcctcatc ttcttgttgg ttcttctgga ctatcaaggt atgttgcccg tttgtcctct 480 aattccagga tcatcaacca ccagtacggg accctgccga acctgcacga ctcttgctca 540 aggaacctct atgtttccct catgttgctg ttcaaaacct tcggacggaa attgcacttg 600 tattcccatc ccatcatcat gggctttcgg aaaattccta tgggagtggg cctcagcccg 660 tttctcctgg ctcagtttac tagtgccatt tgttcagtgg ttcgccgggc tttcccccac 720 tgtctggctt tcagttatat ggatgatgtg gtattggggg ccaagtctgt acaacatctt 780 gagtcccttt atacctctgt taccaatttt cttttgtctt tgggtataca tttaaatccc 840 aacaaaacaa aacgatgggg atattctctt aatttcatgg gatatgtaat tgggagttgg 900 gggtcattac cacaggaaca catccgaatg aaaatcaaag actgttttag aaaactccct 960 gttaaccggc ctattgattg gaaagtatgt caaagaattg tgggtctttt gggctttgct 1020 gcccctttta cacaatgtgg atatcctgct ttaatgcctc tgtatgcgtg tgttcaatcg 1080 aagcaggctt tcactttctc gccaacttac aaggccttc tgtgtaaaca atacctgaac ctttaccccg ttgcccggca acggccaggt ctgtgccaag tgtttgctga tgcaaccccc actggctggg gcttggccat aggccatcag cgcatgcgtg gaaccttgt ggctcctctg ccgatccata ctgcggaact cctagccgct tgttttgctc gcagcaggtc tggagcgaaa cttatcggga cggataattc tgtcgttctc tcccggaaat atacatcatt tccatggctg ctaggctgtg ctgccaactg gatcctgcga gggacgtcct ttgtctacgt cccgtcagcg 1440 ctgaatcctg cggacgaccc gtctcggggt cgcttgggga tctatcgtcc ccttctccgt ctgccgttcc ggccgaccac ggggcgcacc tctctttacg cggtctcccc gtctgtgcct 1560 tctcatctgc cggaccgtgt gcacttcgct tcacctctgc acgtcgcatg gagaccaccg 1620 tgaacgccca tcaaatcttg cccaaggtct tacataagcg gactcttgga ctttctgcaa tgtcaacgac cgaccttgag gcatacttca aagactgttt gtttaaagac tgggaggagt tgggggagg together aaggtctttg tactaggagg ctgtaggcat aaattggtct gcgcaccagc accatgcaac tttttcacct ctgcctaatc atctcttgtt catgtcctac 1860 tgttcaagcc tccaagctgt gccttgggtg gctttggggc atggacattg acccttataa 1920 agaatttgga gctactgtgg agttactctc gttttgccg tctgacttct ttccgtcagt 1980 tagagatctt ctagataccg cctcagctct gtatcgggat gccttagaat ctcctgagca 2040 ttgttcacct caccatactg cactcaggca agccattctt tgctgggggg aactaatgac 2100 tctagctacc tgggtgggtg taaatttgga agatccagca tccagggacc tagtagtcag 2160 ttatgtcaat actaatatgg gcctaaagtt caggcaatta ttgtggtttc acatttcttg 2220 tctcacttt ggaagagaaa ccgtcataga gtatttggtg tcttttggag tgtggattcg 2280 cactcctcca gcttatagac caccaaatgc ccctatctta tcaacacttc cggagaatac 2340 tgttgttaga cgaagaggca ggtcccctag aagaagaact ccctcgcctc gcagacgaag 2400 atctcaatcg ccgcgtcgca gaagatctca atctccagct tcccaatgtt agtattcctt 2460 ggactcacaa ggtgggaaat tttacgggcc tttactcttc tactatacct gtctttaatc 2520 ctaactggaa aactccatct tttcctgata ttcatttgca ccaagacatt attaacaaat 2580 gtgaacaatt tgtaggtcct ctaacagtaa atgaaaaacg aagattaaac ttagtcatgc 2640 ctgctagatt ttttcccatc tctacgaaat atttgcccct agagaagggt ataaaacctt 2700 attatccaga taatgtagtt aatcattact tccaaaccag acactattta cataccctat 2760 ggaaggcggg catcttatat aaacgggaaa ctacacgtag cgcctcattt tgtgggtcac 2820 cttatcttg ggaagaag ctacatcatg gggctttctt ggacggtccc tctcgaatgg 2880 gggaagaatc attccaccac caatcctctg ggattttttc ccgaccacca gttggatcca 2940 gcattcagag caaacaccag aaatccagat tgggaccaca atcccgacaa agaccactgg 3000 agaagcca acaaggtagg agtgggagca ttcgggccgg ggttcactcc cccacacgga 3060 ggccttttgg ggtggagccc tcaggctcaa ggcatgctaa aaacattgcc agcagatccg 3120 cctcctgcct ccaccaatcg gcagtcagga aggcagccta ccccaatcac tccacctttg 3180 agagacactc atcctcaggc catgcagtgg aa 3212 <210> 46 <211> 3215 <212> DNA <213> Hepatitis B virus <400> 46 ctccactcag ttccaccagg ctctgttaga tccgagagta agggctctgt attttcctgc 60 tggtggctcc agttcagaga cacagaaccc tgctccgact attgcctctc tcacatcatc 120 aatcttcttg aagactgggg gccctgctac gaacatggac aacatcacat caggactcct 180 aggacccctg ctcgtgttac aggcggtgtg tttcttgttg acaaaaatcc tcacaatacc 240 acagagtcta gactcgtggt ggacttctct caattttcta gggggaacac ccgggtgtcc 300 tggccaaaat tcgcagtccc caacctccaa tcacttacca acctcctgtc ctccaacttg 360 tcctggctat cgctggatgt gtctgcggcg ttttatcatc ttcctcttca tcctgctgct 420 atgcctcatc ttcttgttgg ttcttctgga ctatcaaggt atgttgcccg tttgtcctct 480 acttccagga tccacgacca ccagcacggg accatgcaaa acctgcacaa ctcttgctca 540 aggaacctct atgtttccct cttgctgctg ttccaaaccc tcggacggaa actgcacttg 600 tattcccatc ccatcatcct gggctttagg aaaataccta tgggagtggg cctcagcccg 660 tttctcctgg ctcagtttac tagtgcaatt tgttcagtgg tgcgtagggc tttcccccac 720 tgtctggctt ttagttatat ggatgatctg gtattggggg ccaaatctgt gcagcatctt 780 gagtcccttt ataccgctgt taccaatttt ctgttatctg tgggtatcca tttaaatacc 840 tcgaaaacaa aaagatgggg ttatacccta aatttcatgg gttatgttat tggcagttgg 900 ggatcattac cacaagatca cattgtacaa aaaatcaaag attgttttcg taaacttcct 960 gtaaatcgcc ctattgattg gaaagtttgt caacgcattg tgggtctttt gggctttgcc 1020 gcccccttta ctcaatgtgg ttatcctgct ctcatgcctc tgtatgcctg tataactgct 1080 aaacaggctt ttgtcttttc gccaacttac aaggcctttc tatgtcaaca atacatgaac 1140 ctttaccccg ttgctcggca acggccaggc ctgtgccaag tgtttgctga cgcaaccccc 1200 actggttggg gcttggccat tggccatcag cgcatgcgtg gaacctttgt ggctcctctg 1260 ccgatccata ctgcggaact ccttgcagct tgtttcgctc gcagccggtc tggagcgaaa 1320 ctcatcggca cagacaactc tgttgtcctc tctaggaagt acacctcctt cccatggctg 1380 ctcggttgtg ctgccaactg gatcctacgc gggacgtcct ttgtttacgt cccgtcggcg 1440 ctgaatccag cggacgatcc ctctcggggt cgcttggggc tgtatcgccc ccttctccgt 1500 ctgccgttcc agccgacgac gggtcgcacc tctctttacg cggcctcccc gtctgttcct 1560 tctcgtctgc cggaccgtgt gcacttcgct tcacctctgc acgtcgcatg gagaccaccg 1620 tgaacgcccc tcgaagcttg ccaacagtct tacataagcg gactcttgga ctttcaggaa 1680 ggtcaatcac ctggatcgaa gaatacatca aagactgtgt atttaaggac tgggaggagc 1740 tgggggagga gattaggtta aaggtctttg tattaggagg ctgtaggcat aaattggtct 1800 gttcaccagc accatgcaac tttttcacct ctgcctaatc atcttttgtt catgtcctac 1860 tgttcaagcc tccaagctgt gccttgggtg gctttggggc atggacattg acccttataa 1920 agaatttgga gcttctgtgg aattactctc ttttttgcct tctgacttct tcccgtcagt 1980 tcgggaccta ctcgacaccg cttcagccct ctaccgggat gctttagaat caccagaaca 2040 ttgcacacct aaccataccg ctctcaggca agctatattg tgctggggtg agttaatgac 2100 tttggcttcc tgggtgggca ataacttgga agatcctgct gctagggacc tagtggttaa 2160 ctatgtcaat actaacatgg gcctaaaaat tagacaattg ctgtggtttc acatttcctg 2220 ccttactttt ggaagagaaa cagttcttga gtatttggtg tcttttggag tgtggattcg 2280 cactcctcct gcttatagac caccaaatgc ccctatctta tccacacttc cggaaactac 2340 tgttgttaga cgacgaggca ggtcccctcg aagaagaact ccctcgcctc gcagacgaag 2400 gtctcaatcg ccgcgtcgca gaagatctca atctccagct tcccaatgtt agtattcctt 2460 ggactcataa ggtgggaaat tttacgggac tctattcctc tactgttcct acttttaatc 2520 ctgactggtt aactccttct tttcctgaca ttcatttaca tcaagatttg atacacaaat 2580 gtgaacaatt tgtaggccct ctcacaaaaa atgaattgag aagattaaaa ttagttatgc 2640 catccagatt ttttcctaag gttaccaaat attttcctat ggaaaaggga attaaaccct 2700 attatcctga taacgtggtt aatcattatt ttaagaccag acactatttg catactttat 2760 ggaargcrgg cattctatat aagagagaat ccacacgtag cgcctcattt tgtgggtcac 2820 catattcttg ggaacaagag ctacagcatg ggagcacctc tatcaacgac tcgaaggggc 2880 atgggacaga atctctctgt acccaatcct ctgggattct ttccagacca tcagctggat 2940 cctctattca gggcaaattc cagcagtccc gactgggact tcaacaaaaa caaggacaat 3000 tggccaatgg caaacaaggt aggagtggga ggatacggtc ctgggttcac acccccacac 3060 ggtggcctgt tggggtggag tccacaggca cagggtgtgc ttacaacatt gccagcagat 3120 ccgcctcctg cttccaccaa tcggcggtcc gggagaaaac caaccccagt ctctccacct 3180 ctaagagaca ctcatccaca ggccatgcag tggaa 3215 <210> 47 <211> 3248 <212> DNA <213> Hepatitis B virus <400> 47 ctctacagca ttccaccaag ctctacaaaa tcccaaagtc aggggcctgt attttcctgc 60 tggtggctcc agttcaggga tagtgaaccc tgttccgact attgcctctc acatctcgtc 120 aatcttctcc aggattgggg accctgcacc gaacatggag aacatcacat caggattcct 180 aggacccctg ctcgtgttac aggcggggtt tttcttgttg acaagaatcc tcacaatacc 240 gcagagtcta gactcgtggt ggacttctct caattttcta gggggagtgc ccgtgtgtcc 300 tggcctaaat tcgcagtccc caacctccaa tcactcacca atctcctgtc ctccaacttg 360 tcctggctat cgctggatgt gtctgcggcg ttttatcata ttcctcttca tcctgctgct 420 atgcctcatc ttcttgttgg ttcttctgga ctatcaaggt atgttgcccg tttgtcctct 480 gattccagga tcctcgacca ccagcacggg accctgcaaa acctgcacga ctcctgctca 540 aggcaactct atgtatccct catgttgctg tacaaaacct tcggacggaa attgcacctg 600 tattcccatc ccatcatctt gggctttcgc aaaataccta tgggagtggg cctcagtccg 660 tttctcttgg ctcagtttac tagtgccatt tgttcagtgg ttcgtagggc tttcccccac 720 tgtctggctt tcagctatat ggatgatgtg gtattggggg ccaaatctgt acaacatctt 780 gagtcccttt ataccgctgt taccaatttt cttttgtctt tgggtataca tctaaaccct 840 aacaaaacaa aaagatgggg ttattcctta aattttatgg gatatgtaat tggaagttgg 900 ggtactttgc cacaagaaca catcacacag aaaattaagc aatgttttcg gaaactccct 960 gttaacaggc caattgattg gaaagtctgt caacgaataa ctggtctgtt gggtttcgct 1020 gctcctttta cccaatgtgg ttaccctgcc ttaatgcctt tatatgcatg tatacaagct 1080 aagcaggctt ttactttctc gccaacttat aaggcctttc tctgtaaaca atacatgaac 1140 cttaccccg ttgctaggca acggcccggt ctgtgccaag tgtttgctga cgcaaccccc 1200 actggttggg gcttggccat cggccatcag cgcatgcgtg gaacctttgt ggctcctctg 1260 ccgatccata ctgcggaact cctagctgct tgttttgctc gcagccggtc tggagcaaaa 1320 ctcattggga ctgacaattc tgtcgtcctt tctcggaaat atacatcctt tccatggctg 1380 ctaggctgtg ctgccaactg gatccttcgc gggacgtcct ttgtttacgt cccgtcagcg 1440 ctgaatccag cggacgaccc ctcccggggc cgtttggggc tctgtcgccc cttctccgt 1500 ctgccgttcc tgccgaccac ggggcgcacc tctctttacg cggtctcccc gtctgttcct 1560 tctcatctgc cggaccgtgt gcacttcgct tcacctctgc acgttacatg gaaaccgcca 1620 tgaacacctc tcatcatcta ccaaggcagt tatataagag gactcttgga ctgtttgtta 1680 tgtcaacaac cgggatggag aaatacttca aggactgtgt ttttgctgag tgggaagaat 1740 taggcaatga gtccaggtta atgacctttg tattaggagg ctgtaggcat aaattggtct 1800 gcgcaccagc accatgtaac tttttcacct ctgcctaatc atctcttgtt catgtcctac 1860 tgttcaagcc tccaagctgt gccttgggtg gctttagggc atggatagaa caactttgcc 1920 atatggcctt tttggcttag acattgaccc ttaataaagaa tttggagcta ctgtggagtt 1980 gctctcgttt ttgccttctg actttttcc gtctgttcgt gatcttctcg acaccgcttc 2040 agctttgtac cgggaatcct tagagtcctc tgatcattgt tcgcctcacc atacagcact 2100 caggcaagca attctgtgct ggggtgagtt gatgactcta gctacctggg tgggtaataa 2160 tttggaagat ccagcatcca gagatttggt ggtcaattat gttaatacta atatgggttt 2220 aaaaatcagg caactattgt ggtttcacat ttcctgtctt acttttggga gagaaaccgt 2280 tcttgagtat ttggtgtctt ttggagtgtg gattcgcact cctcctgctt atagaccacc 2340 aaatgcccct atcctatcaa cacttccgga gactactgtt gttagacgaa gaggcaggtc 2400 ccctcgaaga agaactccct cgcctcgcag acgaagatct caatcgccgc gtcgcagaag 2460 atctgcatct ccagcttccc aatgttagta ttccttggac tcacaaggtg ggaaacttta 2520 cggggctgta ttcttctact atacctgtct ttaatcctga ttggcaaact ccttcttttc 2580 caaatatcca tttgcatcaa gacattataa ctaaatgtga acaatttgtg ggccctctca 2640 cagtaaatga gaaacgaaga ttaaaactag ttatgcctgc cagatttttc ccaaactcta 2700 ctaaatattt accattagac aaaggtatca aaccgtatta tccagaaaat gtagttaatc 2760 attacttcca gaccagacat tatttacata ccctttggaa ggcgggtatt ctatataaga 2820 gagaaacatc ccgtagcgct tcatttttgtg ggtcaccata tacttgggaa caagatctac 2880 agcatggggc tttcttggac ggtccctctc gagtggggaa agaacctttc caccagcaat 2940 cctctaggat tccttcccga tcaccagttg gacccagcat tcagagcaaa taccaacaat 3000 ccagattggg acttcaatcc caaaaaggac ccttggccag aggccaacaa ggtaggagtt 3060 ggagcctatg gacccgggtt cacccctcca cacggaggcc ttttggggtg gagccttcag 3120 tctcagggca cactaacaac tttgccagca gatccgcctc ctgcctccac caatcgtcag 3180 tcagggaggc agcctactcc catctctcca ccactaagag acagtcatcc tcaggccatg 3240 cagtggaa 3248 <210> 48 <211> 3215 <212> DNA <213> Hepatitis B virus <400> 48 ctcaacacag ttccaccaag cactgttgga tccgagagta agggggctgt attttcctgc 60 tggtggctcc agttcagaaa cacagaaccc tgctccgact attgcctctc tcacatcatc 120 aatcttctcg aagactgggg accctgctat gaacatggag aacatcacat caggactcct 180 aggacccctt ctcgtgttac aggcggtgtg tttcttgttg acaaaaatcc tcacaatacc 240 aaagagtcta gactcgtggt ggacttctct caattttcta ggggtaccac ccgggtgtcc 300 tggccaaaat tcgcagtccc caatctccaa tcacttacca acctcctgtc ctccaacttg 360 tcctggctat cgttggatgt gtctgcggcg ttttatcatc ttcctcttca tcctgctgct 420 atgcctcatc ttcttgttgg ttcttctgga ctatcaaggt atgttgcccg tgtgtcctct 480 acttccagga tcwacaacca ccagcacggg accctgcaaa acctgcacca ctcttgctca 540 aggaacctct atgtttccct cctgctgctg taccaaacct tcggacggaa attgcacctg 600 tattcccatc ccatcatctt gggctttcgg aaaataccta tgggagtggg cctcagcccg 660 tttctcttgg ctcagtttac tagtgcaatt tgttcagtgg tgcgtagggc tttcccccac 720 tgtctggctt ttagttatat ggatgatctg gtattggggg ccaaatctgt gcagcatctt 780 gagtcccttt ataccgctgt taccaatttt ttgttatctg tgggcatcca tttgaacaca 840 gctaaaacaa aatggtgggg ttattccctt cactttatgg gttatataat tgggagttgg 900 gggaccttgc ctcaggaaca tattgtgcat aaaatcaaag attgctttcg caaacttccc 960 gtgaatagac ccattgattg gaaggtttgt caacgcattg tgggtctttt gggctttgca 1020 gcccctttta ctcaatgtgg ttatcctgct ctcatgccct tgtatgcctg tattrccgct 1080 aagcaggctt ttgttttctc gccaacttac aaggcctttc tctgtaaaca atacatgaac 1140 ctttaccccg ttgctcggca acggccaggc ctttgccaag tgtttgctga cgcaaccccc 1200 actggctggg gcttggcgat tggccatcag cgcatgcgcg gaacctttgt ggctcctctg 1260 cccatccata ctgcggaact cctagccgct tgtttcgctc gcagcaggtc tggagcggac 1320 attatcggca ctgacaactc cgttgtcctt tctcggaagt acacctcctt cccatggctg 1380 ctaggctgtg ctgccaactg gatcctgcgc gggacgtcct ttgtctacgt cccgtcggcg 1440 ctgaatcctg cggacgaccc ctctcgtggt cgcttggggc tctgccgccc tcttctccgc 1500 ctgccgttcc ggccgacgac gggtcgcacc tctctttacg cggactcccc gcctgtgcct 1560 tctcatctgc cggcccgtgt gcacttcgct tcacctctgc acgtcgcatg gagaccaccg 1620 tgaacgcccc ttggaacttg ccaacaacct tacataagag gactcttgga ctttcgcccc 1680 ggtcaacgac ctggattgag gaatacatca aagactgtgt atttaaggac tgggaggagt 1740 cgggggagga gttgaggtta aaggtctttg tattaggagg ctgtaggcat aaattggtct 1800 gttcaccagc accatgcaac tttttcacct ctgcctaatc atcttttgtt catgtcccac 1860 tgttcaagcc tccaagctgt gccttgggtg gctttggggc atggacattg acccttataa 1920 agaatttgga gcttctgtgg agttactctc atttttgcct tctgacttct tcccgtctgt 1980 ccgggaccta ctcgacaccg cttcagccct ctaccgagat gccttagaat caccagaaca 2040 ttgcaccccc aaccacactg ctctcaggca agctattttg tgctggggtg agttgatgac 2100 cttggcttcc tgggtgggca ataatttaga ggatcctgca gcaagagatc tagtagttaa 2160 ttatgtcaat actaacatgg gcctaaaaat tagacaatta ttatggtttc acatttcttg 2220 ccttacattt ggaagagaaa ctgtgcttga gtatttggtg tcttttggag tgtggattcg 2280 cactccacct gcttatagac caccaaatgc ccctatccta tcaacacttc cggagactac 2340 tgttgttaga caacgaggca gggcccctag aagaagaact ccctcgcctc gcagacgaag 2400 atctcaatct ccgcgtcgca gaagatctca atctccagct tcccaatgtt agtattcctt 2460 ggactcataa ggtgggaaac tttaccggtc tttactcctc tactatacct gttttcaatc 2520 ctgactggtt aactccttct tttcctgaca ttcacttgca tcaagatctg atacaaaaat 2580 gtgaacaatt tgtaggccca ctcactacaa atgaaaggag acgattgaaa ctaattatgc 2640 cagctaggtt ttatcccaaa gttactaaat acttcccttt ggataaaggt attaagcctt 2700 actatccaga gaatgtggtt aatcattact ttaaaactag acattattta catactttgt 2760 ggaaggcagg aattctatat aagagagaat ccacacatag cgcctcattt tgtgggtcac 2820 catattcctg ggaacaagag ctacagcatg ggagcaccctc tctcaacggc gagaaggggc 2880 atgggacaga atctttctgt gcccaatcct ctgggattct ttccagacca ccagttggat 2940 ccactattca gagcaaattc cagcagtccc gattgggact tcaacacaaa caaggacaat 3000 tggccaatgg caaacaaggt aggagtggga ggcttcggtc cagggttcac accccccacac 3060 ggtggccttc tggggtggag ccctcaggca cagggcattc taacaacctc gccaccagat 3120 ccacctcctg cttccaccaa tcggagagtca ggaagaaagc caaccccagt ctctccacct 3180 3215

Claims

1. Use of a polypeptide consisting of an amino acid sequence derived from hepatitis B virus (HBV) or a pharmaceutical composition thereof in the preparation of a drug for treating fatty liver fibrosis; in, The amino acid sequence of the polypeptide is shown in any one of SEQ ID NOs: 21-40.

2. The use according to claim 1, It is characterized in that The amino acid sequence of the polypeptide is shown in SEQ ID NO:

23.

3. The use according to claim 1, It is characterized in that The N-terminus of the polypeptide contains a hydrophobic group modification group; and / or The polypeptide has a C-terminal modification that stabilizes the polypeptide.

4. The use according to claim 3, It is characterized in that The hydrophobic group is selected from the group consisting of myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, cholesterol and arachidonic acid.

5. The use according to claim 3, It is characterized in that The hydrophobic group is myristic acid.

6. The use according to claim 3, It is characterized in that The C-terminal modification is amidation or prenylation.

7. The use according to claim 1, It is characterized in that The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 23, wherein the polypeptide further comprises an N-terminal myristic acid modification and a C-terminal amine modification.

8. The use according to any one of claims 1 to 7, It is characterized in that The pharmaceutical composition also includes a therapeutically effective amount of at least one second agent.

9. The use according to claim 8, It is characterized in that The second agent is selected from the group consisting of antihyperlipidemic drugs, antihyperglycemic drugs, antidiabetic drugs, antiobesity drugs and bile acid analogs.

10. The use according to claim 8, It is characterized in that The second agent is selected from the group consisting of insulin, metformin, sitagliptin, colesevelam, glipizide, simvastatin, atorvastatin, ezetimibe, fenofibrate, niacin, orlistat, lorcaserin, phentermine, topiramate, obeticholic acid, and ursodeoxycholic acid.

11. The use according to any one of claims 1 to 7, It is characterized in that The pharmaceutical composition is in a dosage form suitable for administration by at least one mode selected from parenteral, intrapulmonary, intranasal, intralesional, intramuscular, intravenous, intraarterial, intraperitoneal and subcutaneous.